WHO Drug Information Vol. 27, No. 3, 2013                                                 Recommended INN: List 70



International Nonproprietary Names for
Pharmaceutical Substances (INN)
RECOMMENDED International Nonproprietary Names:
List 70
Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended
International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution
EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are
selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended
International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or
pharmacy.
Lists of Proposed (1–105) and Recommended (1–66) International Nonproprietary Names can be found in Cumulative List
No. 14, 2011 (available in CD-ROM only).



Dénominations communes internationales
des Substances pharmaceutiques (DCI)
Dénominations communes internationales RECOMMANDÉES:
Liste 70
Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de
Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond.
Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)]
les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes
internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune
recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie.
On trouvera d’autres listes de Dénominations communes internationales proposées (1–105) et recommandées (1–66) dans
la Liste récapitulative No. 14, 2011 (disponible sur CD-ROM seulement).



Denominaciones Comunes Internacionales
para las Sustancias Farmacéuticas (DCI)
Denominaciones Comunes Internacionales RECOMENDADAS:
Lista 70
De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes
Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución
EB15.R7); 1969, 173, 10 (Resolución EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1) EB115.R4
(EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han
sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en
las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la
sustancia respectiva en medicina o en farmacia.
Las listas de Denominaciones Comunes Internacionales Propuestas (1–105) y Recomendadas (1–66) se encuentran
reunidas en Cumulative List No. 14, 2011 (disponible sólo en CD-ROM).



                                                                                                                 275
Recommended INN: List 70                                              WHO Drug Information Vol. 27, No. 3, 2013




 Latin, English, French, Spanish:
 Recommended INN                    Chemical name or description; Molecular formula; Graphic formula

 DCI Recommandée                    Nom chimique ou description; Formule brute; Formule développée

 DCI Recomendada                    Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada




 abiciparum pegolum #
 abicipar pegol                            pegylated composite protein for clinical applications (CPCA), with
                                           alternative scaffold domain to antigen receptors based on ankyrin
                                           repeats, anti-[Homo sapiens VEGFA (vascular endothelial growth
                                           factor A, VEGF-A, VEGF)];
                                           glycyl-seryl-ankyrin repeats (3-35, 36-68, 69-101, 102-123)-lysyl-
                                           dialanyl-bis(triglycyl-seryl) linker (127-134)-cysteinyl (1-135),
                                           conjugated via a maleimide group linker (thioether bond to C135) to
                                           a single linear methoxy polyethylene glycol 20 (mPEG20)

 abicipar pégol                            protéine composite pour applications cliniques (CPCA) pégylée,
                                           avec une charpente de domaine alternative aux récepteurs
                                           d'antigènes basée sur des répétitions ankyrine, anti-[Homo sapiens
                                           VEGFA (vascular endothelial growth factor A, VEGF-A, VEGF)];
                                           glycyl-séryl-domaine à répétitions ankyrine (3-35, 36-68, 69-101,
                                           102-123)-lysyl-dialanyl-linker bis(triglycyl-séryl) (127-134)-cystéinyl
                                           (1-135), conjugué via un linker du groupe maléimide (liaison
                                           thioéther à C135) à une molécule linéaire unique de méthoxy
                                           polyéthylène glycol 20 (mPEG20)

 abicipar pegol                            proteína compuesta para aplicaciones clínicas (CPCA) pegilada, con
                                           una estructura de dominio alternativa a los receptores de antígenos
                                           basada en repeticiones de la ankirina, anti-[Homo sapiens VEGFA
                                           (factor A de crecimiento endotelial vascular, VEGF-A, VEGF)];
                                           glicil-seril-dominio de repeticiones de ankirina (3-35, 36-68, 69-101,
                                           102-123)-lisil-dialanil-conector bis(triglicil-seril) (127-134)-cisteinil
                                           (1-135), conjugado mediante un conector maleimida (enlace tioéter
                                           en C135) en una molécula lineal única de metoxi polietilenglicol 20
                                           (mPEG20)

                                           C617H969N173O199S2 (protein component)

                                           GSDLDKKLLE AARAGQDDEV RILMANGADV NARDSTGWTP LHLAAPWGHP 50
                                           EIVEVLLKNG ADVNAADFQG WTPLHLAAAV GHLEIVEVLL KYGADVNAQD 100
                                           KFGKTAFDIS IDNGNEDLAE ILQKAAGGGS GGGSC                 135



 afoxolanerum
 afoxolaner                                4-{5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-
                                           4,5-dihydro-1,2-oxazol-3-yl}-N-{2-oxo-2-[(2,2,2-
                                           trifluoroethyl)amino]ethyl}naphthalene-1-carboxamide

 afoxolaner                                4-{5-[3-chloro-5-(trifluorométhyl)phényl]-5-(trifluorométhyl)-
                                           4,5-dihydro-1,2-oxazol-3-yl}-N-{2-oxo-2-[(2,2,2-
                                           trifluoroéthyl)amino]éthyl}naphtalène-1-carboxamide

 afoxolaner                                4-{5-[3-cloro-5-(trifluorometil)fenil]-5-(trifluorometil)-4,5-dihidro-
                                           1,2-oxazol-3-il}-N-{2-oxo-2-[(2,2,2-trifluoroetil)amino]etil}naftaleno-
                                           1-carboxamida


276
WHO Drug Information Vol. 27, No. 3, 2013                                                       Recommended INN: List 70




                                            C26H17ClF9N3O3

                                                        F3C       O N
                                            F3C
                                                                                                           and enantiomer
                                                                                            O              et énantiomère
                                                                                    H
                                                                                    N                      y enantiómero
                                                                                                N    CF3
                                                    Cl                                          H
                                                                                O




 afuresertibum
 afuresertib                                N-[(2S)-1-amino-3-(3-fluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-
                                            1-methyl-1H-pyrazol-5-yl)thiophene-2-carboxamide

 afurésertib                                N-[(2S)-1-amino-3-(3-fluorophényl)propan-2-yl]-5-chloro-4-(4-chloro-
                                            1-méthyl-1H-pyrazol-5-yl)thiophène-2-carboxamide

 afuresertib                                N-[(2S)-1-amino-3-(3-fluorofenil)propan-2-il]-5-cloro-4-(4-cloro-
                                            1-metil-1H-pirazol-5-il)tiofeno-2-carboxamida

                                            C18H17Cl2FN4OS

                                               Cl   Cl
                                                              S
                                                                      H
                                                                      N                 F
                                            N N
                                                  CH3             O        H
                                                                          NH2




 albutrepenonacogum alfa #
 albutrepenonacog alfa                      human coagulation factor IX (EC 3.4.21.22, Christmas factor, plasma
                                            thromboplastin component) 148-threonine variant fusion protein with
                                            prolyl(human coagulation factor IX 148-threonine variant-(137-153)-
                                            peptide) fusion protein with human serum albumin, produced in CHO
                                            cells (alfa glycoform)

 albutrépénonacog alfa                      variant 148-thréonine du facteur IX humain de la coagulation (EC
                                            3.4.21.22, facteur Christmas, facteur antihémophilique B) protéine
                                            de fusion avec le prolyl(variant 148-thréonine du facteur IX humain
                                            de la coagulation-(137-153)-peptide), protéine de fusion avec
                                            l'albumine sérique humaine, produit par culture de cellules CHO
                                            (glycoforme alfa)

 albutrepenonacog alfa                      variante 148-treonina del factor IX humano de coagulación (EC
                                            3.4.21.22, factor Christmas, factor antihemofílico B) proteína de
                                            fusión con prolil(variante 148-treonina del factor IX humano de la
                                            coagulación-(137-153)-péptido), proteína de fusión con albumina
                                            sérica humana, producida por cultivo de células CHO (glicoforma
                                            alfa)




                                                                                                                        277
Recommended INN: List 70                                           WHO Drug Information Vol. 27, No. 3, 2013




                           C5077H7846N1367O1588PS67 (peptide)
                           Sequence / Séquence / Secuencia
                           YNSGKLEEFV QGNLERECME EKCSFEEARE                      VFENTERTTE     FWKQYVDGDQ        50
                           CESNPCLNGG SCKDDINSYE CWCPFGFEGK                      NCELDVTCNI     KNGRCEQFCK        100
                           NSADNKVVCS CTEGYRLAEN QKSCEPAVPF                      PCGRVSVSQT     SKLTRAETVF        150
                           PDVDYVNSTE AETILDNITQ STQSFNDFTR                      VVGGEDAKPG     QFPWQVVLNG        200
                           KVDAFCGGSI VNEKWIVTAA HCVETGVKIT                      VVAGEHNIEE     TEHTEQKRNV        250
                           IRIIPHHNYN AAINKYNHDI ALLELDEPLV                      LNSYVTPICI     ADKEYTNIFL        300
                           KFGSGYVSGW GRVFHKGRSA LVLQYLRVPL                      VDRATCLRST     KFTIYNNMFC        350
                           AGFHEGGRDS CQGDSGGPHV TEVEGTSFLT                      GIISWGEECA     MKGKYGIYTK        400
                           VSRYVNWIKE KTKLTPVSQT SKLTRAETVF                      PDVDAHKSEV     AHRFKDLGEE        450
                           NFKALVLIAF AQYLQQCPFE DHVKLVNEVT                      EFAKTCVADE     SAENCDKSLH        500
                           TLFGDKLCTV ATLRETYGEM ADCCAKQEPE                      RNECFLQHKD     DNPNLPRLVR        550
                           PEVDVMCTAF HDNEETFLKK YLYEIARRHP                      YFYAPELLFF     AKRYKAAFTE        600
                           CCQAADKAAC LLPKLDELRD EGKASSAKQR                      LKCASLQKFG     ERAFKAWAVA        650
                           RLSQRFPKAE FAEVSKLVTD LTKVHTECCH                      GDLLECADDR     ADLAKYICEN        700
                           QDSISSKLKE CCEKPLLEKS HCIAEVENDE                      MPADLPSLAA     DFVESKDVCK        750
                           NYAEAKDVFL GMFLYEYARR HPDYSVVLLL                      RLAKTYETTL     EKCCAAADPH        800
                           ECYAKVFDEF KPLVEEPQNL IKQNCELFEQ                      LGEYKFQNAL     LVRYTKKVPQ        850
                           VSTPTLVEVS RNLGKVGSKC CKHPEAKRMP                      CAEDYLSVVL     NQLCVLHEKT        900
                           PVSDRVTKCC TESLVNRRPC FSALEVDETY                      VPKEFNAETF     TFHADICTLS        950
                           EKERQIKKQT ALVELVKHKP KATKEQLKAV                      MDDFAAFVEK     CCKADDKETC        1000
                           FAEEGKKLVA ASQAALGL                                                                    1018

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           18-23     51-62      56-71     73-82      88-99      95-109 111-124
                           132-289 206-222 336-350 361-389 486-495 508-524 523-534
                           557-602 601-610 633-679 678-686 698-712 711-722 749-794
                           793-802 825-871 870-881 894-910 909-920 947-992 991-1000

                           Modified residues / Résidus modifiés / Restos modificados
                                                                                                              H   NH2
                                    E
                           7-8-15-17-20-21-26           HO2C   H    NH2                D           HO2C
                             27-30-33-36-40                                           64                           CO2H
                              4-carboxyGlu          HO2C             CO2H        3-hydroxyAsp
                                                                                                          OH

                                                                                                                   H    NH2
                                 Y         HO       O
                                                S                                       S            O        O
                                155                                 H   NH2                               P               CO2H
                                                                                       158
                             O-sulfoTyr       O O                                 O-phosphonoSer     HO OH
                                                                          CO2H

                           Glycosylation sites (N,S,T) / Sites de glycosylation (N,S,T) / Posiciones de glicosilación (N,S,T)
                           Ser-53* Ser-61* Asn-157 Thr-159* Asn-167 Thr-169* Thr-172* Thr-179*
                           * potential sites / sites potentiels / posiciones posibles




 aldoxorubicinum
 aldoxorubicin             N'-[(1E)-1-{(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-
                           hexopyranosyl)oxy]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-
                           1,2,3,4,6,11-hexahydrotetracen-2-yl}-2-hydroxyethylidene]-
                           6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanohydrazide

 aldoxorubicine            N'-[(1E)-1-{(2S,4S)-4-[(3-amino-2,3,6-tridéoxy-α-L-lyxo-
                           hexopyranosyl)oxy]-2,5,12-trihydroxy-7-méthoxy-6,11-dioxo-
                           1,2,3,4,6,11-hexahydrotétracén-2-yl}-2-hydroxyéthylidène]-
                           6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanohydrazide

 aldoxorubicina            N'-[(1E)-1-{(2S,4S)-4-[(3-amino-2,3,6-tridesoxi-α-L-lyxo-
                           hexopiranosil)oxi]-2,5,12-trihidroxi-7-metoxi-6,11-dioxo-
                           1,2,3,4,6,11-hexahidrotetracen-2-il}-2-hidroxietilideno]-
                           6-(2,5-dioxo-2,5-dihidro-1H-pirrol-1-il)hexanohidrazida




278
WHO Drug Information Vol. 27, No. 3, 2013                                                         Recommended INN: List 70


                                            C37H42N4O13
                                                                                                               O
                                                                              O
                                                                                                           N
                                                                                   NH
                                                       O      OH              N                       O
                                                                                        OH
                                                                              OH        NH2


                                                OCH3 O        OH H O                         OH
                                                                               O
                                                                                        CH3



 alectinibum
 alectinib                                  9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-
                                            6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile

 alectinib                                  9-éthyl-6,6-diméthyl-8-[4-(morpholin-4-yl)pipéridin-1-yl]-11-oxo-
                                            6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile

 alectinib                                  9-etil-6,6-dimetil-8-[4-(morfolin-4-il)piperidin-1-il]-11-oxo-6,11-dihidro-
                                            5H-benzo[b]carbazol-3-carbonitrilo

                                            C30H34N4O2
                                                                               O
                                                                                                      CN
                                                        H3C

                                                              N                          N
                                                                                         H
                                                                         H3C       CH3
                                                   N
                                            O



 apitolisibum
 apitolisib                                 (2S)-1-(4-{[2-(2-aminopyrimidin-5-yl)-7-methyl-4-(morpholin-
                                            4-yl)thieno[3,2-d]pyrimidin-6-yl]methyl}piperazin-1-yl)-
                                            2-hydroxypropan-1-one

 apitolisib                                 (2S)-1-(4-{[2-(2-aminopyrimidin-5-yl)-7-méthyl-4-(morpholin-
                                            4-yl)thiéno[3,2-d]pyrimidin-6-yl]méthyl}pipérazin-1-yl)-
                                            2-hydroxypropan-1-one

 apitolisib                                 (2S)-1-(4-{[2-(2-aminopirimidin-5-il)-7-metil-4-(morfolin-4-il)tieno[3,2-
                                            d]pirimidin-6-il]metil}piperazin-1-il)-2-hidroxipropan-1-ona
                                            C23H30N8O3S
                                                                              O

                                                                         N
                                                                                                  O
                                                    N              N
                                                                                                           CH3
                                            H2 N                              S               N
                                                    N              N                              H OH
                                                                                         N

                                                                       H3 C




                                                                                                                       279
Recommended INN: List 70                               WHO Drug Information Vol. 27, No. 3, 2013




 belnacasanum
 belnacasan                1-[(2S)-2-(4-amino-3-chlorobenzamido)-3,3-dimethylbutanoyl]-
                           N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]-L-prolinamide

 belnacasan                1-[(2S)-2-(4-amino-3-chlorobenzamido)-3,3-diméthylbutanoyl]-
                           N-[(2R,3S)-2-éthoxy-5-oxooxolan-3-yl]-L-prolinamide

 belcanasán                1-[(2S)-2-(4-amino-3-clorobenzamido)-3,3-dimetilbutanoil]-
                           N-[(2R,3S)-2-etoxi-5-oxooxolan-3-il]-L-prolinamida

                           C24H33ClN4O6

                           H2N
                                                   O           O                   O
                                             H             H       H
                                             N
                            Cl                         N           N           O
                                             H                     H
                                          O                            H
                                                                           O
                                          H3 C
                                                   CH3                         CH3
                                            H3 C



 bimagrumabum #
 bimagrumab                immunoglobulin G1-lambda2, anti-[Homo sapiens ACVR2B (activin
                           A receptor type IIB, ActR-IIB, ActRIIB) and ACVR2A (activin A
                           receptor type IIA, ActR-II, ActRIIA)], Homo sapiens monoclonal
                           antibody;
                           gamma1 heavy chain (1-445) [Homo sapiens VH (IGHV1-2*02
                           (91.80%) -(IGHD)-IGHJ5*01 [8.8.8] (1-115) -IGHG1*03 (CH1 (116-
                           213), hinge (214-228), CH2 L1.3>A (232), L1.2>A (233) (229-338),
                           CH3 (339-443), CHS (444-445)) (116-445)], (218-216')-disulfide with
                           lambda light chain (1'-217') [Homo sapiens V-LAMBDA (IGLV2-
                           23*02 (90.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')];
                           dimer (224-224'':227-227'')-bisdisulfide

 bimagrumab                immunoglobuline G1-lambda2, anti-[Homo sapiens ACVR2B
                           (récepteur type IIB de l'activine A, ActR-IIB, ActRIIB) et ACVR2A
                           (recepteur type IIA de l’activine A, ActR-II, ActRIIA)], Homo sapiens
                           anticorps monoclonal;
                           chaîne lourde gamma1 (1-445) [Homo sapiens VH (IGHV1-2*02
                           (91.80%) -(IGHD)-IGHJ5*01 [8.8.8] (1-115) -IGHG1*03 (CH1 (116-
                           213), charnière (214-228), CH2 L1.3>A (232), L1.2>A (233) (229-
                           338), CH3 (339-443), CHS (444-445)) (116-445)], (218-216')-
                           disulfure avec la chaîne légère lambda (1'-217') [Homo sapiens
                           V-LAMBDA (IGLV2-23*02 (90.90%) -IGLJ2*01) [9.3.11] (1'-111') -
                           IGLC2*01 (112'-217')]; dimère (224-224'':227-227'')-bisdisulfure

 bimagrumab                inmunoglobulina G1-lambda2, anti-[Homo sapiens ACVR2B
                           (receptor tipo IIB de la activina A, ActR-IIB, ActRIIB) y ACVR2A
                           (receptor tipo IIA de la activina A, ActR-II, ActRIIA)], anticuerpo
                           monoclonal de Homo sapiens;
                           cadena pesada gamma1 (1-445) [Homo sapiens VH (IGHV1-2*02
                           (91.80%) -(IGHD)-IGHJ5*01 [8.8.8] (1-115) -IGHG1*03 (CH1 (116-
                           213), bisagra (214-228), CH2 L1.3>A (232), L1.2>A (233) (229-338),
                           CH3 (339-443), CHS (444-445)) (116-445)], (218-216')-disulfuro con
                           la cadena ligera lambda (1'-217') [Homo sapiens V-LAMBDA
                           (IGLV2-23*02 (90.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01
                           (112'-217')]; dímero (224-224'':227-227'')-bisdisulfuro




280
WHO Drug Information Vol. 27, No. 3, 2013                                                             Recommended INN: List 70



                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            QVQLVQSGAE VKKPGASVKV SCKASGYTFT                  SSYINWVRQA       PGQGLEWMGT        50
                                            INPVSGSTSY AQKFQGRVTM TRDTSISTAY                  MELSRLRSDD       TAVYYCARGG       100
                                            WFDYWGQGTL VTVSSASTKG PSVFPLAPSS                  KSTSGGTAAL       GCLVKDYFPE       150
                                            PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL                  SSVVTVPSSS       LGTQTYICNV       200
                                            NHKPSNTKVD KRVEPKSCDK THTCPPCPAP                  EAAGGPSVFL       FPPKPKDTLM       250
                                            ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV                  EVHNAKTKPR       EEQYNSTYRV       300
                                            VSVLTVLHQD WLNGKEYKCK VSNKALPAPI                  EKTISKAKGQ       PREPQVYTLP       350
                                            PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE                  SNGQPENNYK       TTPPVLDSDG       400
                                            SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL                  HNHYTQKSLS       LSPGK            445

                                            Light chain / Chaîne légère / Cadena ligera
                                            QSALTQPASV SGSPGQSITI SCTGTSSDVG                  SYNYVNWYQQ       HPGKAPKLMI 50
                                            YGVSKRPSGV SNRFSGSKSG NTASLTISGL                  QAEDEADYYC       GTFAGGSYYG 100
                                            VFGGGTKLTV LGQPKAAPSV TLFPPSSEEL                  QANKATLVCL       ISDFYPGAVT 150
                                            VAWKADSSPV KAGVETTTPS KQSNNKYAAS                  SYLSLTPEQW       KSHRSYSCQV 200
                                            THEGSTVEKT VAPTECS                                                            217

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-96 142-198             259-319 365-423
                                                     22''-96'' 142''-198'' 259''-319'' 365''-423''
                                            Intra-L 22'-90'       139'-198'
                                                      22'''-90''' 139'''-198'''
                                            Inter-H-L 218-216' 218''-216'''
                                            Inter-H-H 224-224'' 227-227''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            H CH2 N84.4:
                                            295, 295''




 brilacidinum
                                                4   6
 brilacidin                                 N ,N -bis[3-{[5-(carbamimidamido)pentanoyl]amino}-
                                            2-{[(3R)-pyrrolidin-3-yl]oxy}-5-(trifluoromethyl)phenyl]pyrimidine-
                                            4,6-dicarboxamide
                                                4   6
 brilacidine                                N ,N -bis[3-{[5-(carbamimidamido)pentanoyl]amino}-
                                            2-{[(3R)-pyrrolidin-3-yl]oxy}-5-(trifluorométhyl)phényl]pyrimidine-
                                            4,6-dicarboxamide
                                                4   6
 brilacidina                                N ,N -bis[3-{[5-(carbamimidamido)pentanoil]amino}-
                                            2-{[(3R)-pirrolidin-3-il]oxi}-5-(trifluorometil)fenil]pirimidina-
                                            4,6-dicarboxamida

                                            C40H50F6N14O6

                                                    HN                                                         NH

                                                              O              N       N               O
                                                        H H          H                       H           H H
                                            O           N            N                       N             N         O

                                                                         O               O

                                                              CF3                                 F 3C

                                                         HN        NH2                        H2N         NH

                                                              NH                                     NH




                                                                                                                                          281
Recommended INN: List 70                                      WHO Drug Information Vol. 27, No. 3, 2013


 concizumabum #
 concizumab                immunoglobulin G4-kappa, anti-[Homo sapiens TFPI (tissue factor
                           pathway inhibitor, lipoprotein-associated coagulation inhibitor)],
                           humanized monoclonal antibody;
                           gamma4 heavy chain (1-448) [humanized VH (Homo sapiens
                           IGHV3-21*01 (85.70%) -(IGHD)-IGHJ3*01 M11>T (116)) [8.8.14] (1-
                           121) -Homo sapiens IGHG4*01 (CH1 (122-219), hinge S10>P (229)
                           (220-231), CH2 (232-341), CH3 (342-446), CHS (447-448)) (122-
                           448)], (135-219')-disulfide with kappa light chain (1'-219') [humanized
                           V-KAPPA (Homo sapiens IGKV2-29*02 (90.00%) -IGKJ4*01)
                           [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimer (227-
                           227":230-230")-bisdisulfide

 concizumab                immunoglobuline G4-kappa, anti-[Homo sapiens TFPI (inhibiteur de
                           la voie du facteur tissulaire, inhibiteur de la coagulation associé aux
                           lipoprotéines)], anticorps monoclonal humanisé;
                           chaîne lourde gamma4 (1-448) [VH humanisé (Homo sapiens
                           IGHV3-21*01 (85.70%) -(IGHD)- IGHJ3*01 M11>T (116)) [8.8.14] (1-
                           121) -Homo sapiens IGHG4*01 (CH1 (122-219), charnière S10>P
                           (229) (220-231), CH2 (232-341), CH3 (342-446), CHS (447-448))
                           (122-448)], (135-219')-disulfure avec la chaîne légère kappa (1'-219')
                           [V-KAPPA humanisé (Homo sapiens IGKV2-29*02 (90.00%) -
                           IGKJ4*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')];
                           dimère (227-227":230-230")-bisdisulfure

 concizumab                inmunoglobulina G4-kappa, anti-[Homo sapiens TFPI (inhibidor de la
                           vía del factor tisular, inhibidor de la coagulación asociado a
                           lipoproteínas)], anticuerpo monoclonal humanizado;
                           cadena pesada gamma4 (1-448) [VH humanizado (Homo sapiens
                           IGHV3-21*01 (85.70%) -(IGHD)- IGHJ3*01 M11>T (116)) [8.8.14] (1-
                           121) -Homo sapiens IGHG4*01 (CH1 (122-219), bisagra S10>P
                           (229) (220-231), CH2 (232-341), CH3 (342-446), CHS (447-448))
                           (122-448)], (135-219')-disulfuro con la cadena ligera kappa (1'-219')
                           [V-KAPPA humanizado (Homo sapiens IGKV2-29*02 (90.00%) -
                           IGKJ4*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')];
                           dímero (227-227":230-230")-bisdisulfuro
                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVESGGG LVKPGGSLRL SCAASGFTFS                  NYAMSWVRQT       PEKRLEWVAT        50
                           ISRSGSYSYF PDSVQGRFTI SRDNAKNSLY                  LQMNSLRAED       TAVYYCARLG       100
                           GYDEGDAMDS WGQGTTVTVS SASTKGPSVF                  PLAPCSRSTS       ESTAALGCLV       150
                           KDYFPEPVTV SWNSGALTSG VHTFPAVLQS                  SGLYSLSSVV       TVPSSSLGTK       200
                           TYTCNVDHKP SNTKVDKRVE SKYGPPCPPC                  PAPEFLGGPS       VFLFPPKPKD       250
                           TLMISRTPEV TCVVVDVSQE DPEVQFNWYV                  DGVEVHNAKT       KPREEQFNST       300
                           YRVVSVLTVL HQDWLNGKEY KCKVSNKGLP                  SSIEKTISKA       KGQPREPQVY       350
                           TLPPSQEEMT KNQVSLTCLV KGFYPSDIAV                  EWESNGQPEN       NYKTTPPVLD       400
                           SDGSFFLYSR LTVDKSRWQE GNVFSCSVMH                  EALHNHYTQK       SLSLSLGK         448

                           Light chain / Chaîne légère / Cadena ligera
                           DIVMTQTPLS LSVTPGQPAS ISCKSSQSLL                  ESDGKTYLNW       YLQKPGQSPQ 50
                           LLIYLVSILD SGVPDRFSGS GSGTDFTLKI                  SRVEAEDVGV       YYCLQATHFP 100
                           QTFGGGTKVE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK 150
                           VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE 200
                           VTHQGLSSPV TKSFNRGEC                                                          219

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96 148-204 262-322 368-426
                             22''-96'' 148''-204'' 262''-322'' 368''-426''
                           Intra-L 23'-93' 139'-199'
                             23'''-93''' 139'''-199'''
                           Inter-H-L 135-219' 135''-219'''
                           Inter-H-H 227-227'' 230-230''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           298, 298''




282
WHO Drug Information Vol. 27, No. 3, 2013                                                        Recommended INN: List 70


 copanlisibum
 copanlisib                                 2-amino-N-{7-methoxy-8-[3-(morpholin-4-yl)propoxy]-
                                            2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}pyrimidine-5-carboxamide

 copanlisib                                 2-amino-N-{7-méthoxy-8-[3-(morpholin-4-yl)propoxy]-
                                            2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}pyrimidine-5-carboxamide

 copanlisib                                 2-amino-N-{7-metoxi-8-[3-(morfolin-4-il)propoxi]-
                                            2,3-dihidroimidazo[1,2-c]quinazolin-5-il}pirimidina-5-carboxamida

                                            C23H28N8O4
                                                                            N

                                                                                N       O

                                                  N             O           N       N                 N
                                                                                    H
                                            O                        OCH3
                                                                                                  N       NH2


 deferitazolum
 deferitazole                               (4S)-2-(2-hydroxy-3-{[(methoxyethoxy)ethoxy]ethoxy}phenyl)-
                                            4-methyl-4,5-dihydro-1,3-thiazol-4-carboxylic acid

 déféritazole                               acide (4S)-2-{2-hydroxy-3-{[(méthoxyéthoxy)éthoxy]éthoxy}phenyl)-
                                            4-méthyl-4,5-dihydro-1,3-thiazole-4-carboxylique

 deferitazol                                ácido (4S)-2-(2-hidroxi-4-metil -3-{[(metoxietoxi)etoxi]etoxi}fenil)-
                                            4,5-dihidro-1,3-tiazol-4-carboxílico

                                            C18H25NO7S

                                                  O                 O                                 N
                                            H3C            O                    O                          CO2H
                                                                                        OH        S        CH3



 deleobuvirum
 deleobuvir                                 (2E)-3-(2-{1-[2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-methyl-
                                            1H-indole-6-carboxamido]cyclobutyl}-1-methyl-1H-benzimidazol-
                                            6-yl)prop-2-enoic acid

 déléobuvir                                 acide (2E)-3-(2-{1-[2-(5-bromopyrimidin-2-yl)-3-cyclopentyl-1-méthyl-
                                            1H-indole-6-carboxamido]cyclobutyl}-1-méthyl-1H-benzimidazol-
                                            6-yl)prop-2-énoïque

 deleobuvir                                 ácido (2E)-3-(2-{1-[2-(5-bromopirimidin-2-il)-3-ciclopentil-1-metil-
                                            1H-indol-6-carboxamido]ciclobutil}-1-metil-1H-benzimidazol-
                                            6-il)prop-2-enoico

                                            C34H33BrN6O3




                                                      N
                                                                                        N
                                            Br                                  H                                CO2H
                                                                                N
                                                      N        N                             N
                                                          H3C             O                  CH3




                                                                                                                        283
Recommended INN: List 70                            WHO Drug Information Vol. 27, No. 3, 2013


 delparantagum
                            2
 delparantag               N -{5-[(5-{5-{L-lysylamino}-2-methoxybenzoyl-L-lysylamino}-
                           2-methoxybenzoyl-L-lysyl)amino]-2-methoxybenzoyl}-N-(3-
                           carbamoyl-4-methoxyphenyl)-L-lysinamide
                            2
 delparantag               N -{5-[(5-{5-{L-lysylamino}-2-méthoxybenzoyl-L-lysylamino}-
                           2-méthoxybenzoyl-L-lysyl)amino]-2-méthoxybenzoyl}-
                           N-(3-carbamoyl-4-méthoxyphényl)-L-lysinamide
                            2
 delparantag               N -{5-[(5-{5-{L-lisilamino}-2-metoxibenzoil-L-lisilamino}-
                           2-metoxibenzoil-L-lisil)amino]-2-metoxibenzoil}-N-(3-carbamoil-
                           4-metoxfenil)-L-lisinamida

                           C56H79N13O12

                                     NH2




                                 H                 O
                                           H               H
                                           N
                                                       N
                           H2N                         H
                                     O
                                                   OCH3
                                                           4




 dupilumabum #
 dupilumab                 immunoglobulin G4-kappa, anti-[Homo sapiens IL4R (interleukin 4
                           receptor, IL4RA, IL-4RA, CD124)], Homo sapiens monoclonal
                           antibody;
                           gamma4 heavy chain (1-451) [Homo sapiens VH (IGHV3-23*04
                           (92.90%) -(IGHD)-IGHJ6*01) [8.8.18] (1-125) -IGHG4*01 (CH1 (126-
                           223), hinge S10>P (233) (224-235), CH2 (236-345), CH3 (346-450),
                           CHS K130>del (451)) (126-451)], (139-219')-disulfide with kappa
                           light chain (1'-219') [Homo sapiens V-KAPPA (IGKV2-28*01
                           (96.00%) -IGKJ2*01) [11.3.9] (1'-112') -IGKC*01 (113'-219')]; dimer
                           (231-231'':234-234'')-bisdisulfide

 dupilumab                 immunoglobuline G4-kappa, anti-[Homo sapiens IL4R (récepteur de
                           l'interleukine 4, IL4RA, IL-4RA, CD124)], Homo sapiens anticorps
                           monoclonal;
                           chaîne lourde gamma4 (1-451) [Homo sapiens VH (IGHV3-23*04
                           (92.90%) -(IGHD)-IGHJ6*01) [8.8.18] (1-125) -IGHG4*01 (CH1 (126-
                           223), charnière S10>P (233) (224-235), CH2 (236-345), CH3 (346-
                           450), CHS K130>del (451)) (126-451)], (139-219')-disulfure avec la
                           chaîne légère kappa (1'-219') [Homo sapiens V-KAPPA (IGKV2-
                           28*01 (96.00%) -IGKJ2*01) [11.3.9] (1'-112') -IGKC*01 (113'-219')];
                           dimère (231-231'':234-234'')-bisdisulfure

 dupilumab                 inmunoglobulina G4-kappa, anti-[Homo sapiens IL4R (receptor de la
                           interleukina 4, IL4RA, IL-4RA, CD124)], anticuerpo monoclonal de
                           Homo sapiens;
                           cadena pesada gamma4 (1-451) [Homo sapiens VH (IGHV3-23*04
                           (92.90%) -(IGHD)-IGHJ6*01) [8.8.18] (1-125) -IGHG4*01 (CH1 (126-
                           223),bisagra S10>P (233) (224-235), CH2 (236-345), CH3 (346-
                           450), CHS K130>del (451)) (126-451)], (139-219')-disulfuro con la
                           cadena ligera kappa (1'-219') [Homo sapiens V-KAPPA (IGKV2-
                           28*01 (96.00%) -IGKJ2*01) [11.3.9] (1'-112') -IGKC*01 (113'-219')];
                           dímero (231-231'':234-234'')-bisdisulfuro




284
WHO Drug Information Vol. 27, No. 3, 2013                                                            Recommended INN: List 70



                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            EVQLVESGGG LEQPGGSLRL SCAGSGFTFR                  DYAMTWVRQA       PGKGLEWVSS        50
                                            ISGSGGNTYY ADSVKGRFTI SRDNSKNTLY                  LQMNSLRAED       TAVYYCAKDR       100
                                            LSITIRPRYY GLDVWGQGTT VTVSSASTKG                  PSVFPLAPCS       RSTSESTAAL       150
                                            GCLVKDYFPE PVTVSWNSGA LTSGVHTFPA                  VLQSSGLYSL       SSVVTVPSSS       200
                                            LGTKTYTCNV DHKPSNTKVD KRVESKYGPP                  CPPCPAPEFL       GGPSVFLFPP       250
                                            KPKDTLMISR TPEVTCVVVD VSQEDPEVQF                  NWYVDGVEVH       NAKTKPREEQ       300
                                            FNSTYRVVSV LTVLHQDWLN GKEYKCKVSN                  KGLPSSIEKT       ISKAKGQPRE       350
                                            PQVYTLPPSQ EEMTKNQVSL TCLVKGFYPS                  DIAVEWESNG       QPENNYKTTP       400
                                            PVLDSDGSFF LYSRLTVDKS RWQEGNVFSC                  SVMHEALHNH       YTQKSLSLSL       450
                                            G                                                                                   451

                                            Light chain / Chaîne légère / Cadena ligera
                                            DIVMTQSPLS LPVTPGEPAS ISCRSSQSLL                  YSIGYNYLDW       YLQKSGQSPQ 50
                                            LLIYLGSNRA SGVPDRFSGS GSGTDFTLKI                  SRVEAEDVGF       YYCMQALQTP 100
                                            YTFGQGTKLE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK 150
                                            VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE 200
                                            VTHQGLSSPV TKSFNRGEC                                                          219

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-96        152-208       266-326  372-430
                                                     22''-96'' 152''-208'' 266''-326'' 372''-430''
                                            Intra-L 23'-93' 139'-199'
                                                     23'''-93''' 139'''-199'''
                                            Inter-H-L 139-219' 139''-219'''
                                            Inter-H-H 231-231'' 234-234''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            H CH2 N84.4:
                                            302, 302''



 dusigitumabum #
 dusigitumab                                immunoglobulin G2-lambda2, anti-[Homo sapiens IGF1 (insulin-like
                                            growth factor 1, somatomedin C) and IGF2 (insulin-like growth factor
                                            2, somatomedin A)], Homo sapiens monoclonal antibody;
                                            gamma2 heavy chain (1-446) [Homo sapiens VH (IGHV1-8*01
                                            (100.00%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -IGHG2*01 (CH1
                                            (121-218), hinge (219-230), CH2 (231-339), CH3 (340-444), CHS
                                            (445-446)) (121-446)], (134-216')-disulfide with lambda light chain
                                            (1'-217') [Homo sapiens V-LAMBDA (IGLV1-51*01 (95.90%) -
                                            IGLJ2*01) [8.3.12] (1'-111') -IGLC2*01 (112'-217')]; dimer (222-
                                            222'':223-223'':226-226'':229-229'')-tetrakisdisulfide

 dusigitumab                                immunoglobuline G2-lambda2, anti-[Homo sapiens IGF1 (facteur de
                                            croissance 1 analogue à l'insuline, somatomédine C) et IGF2
                                            (facteur de croissance 2 analogue à l'insuline, somatomédine A)],
                                            Homo sapiens anticorps monoclonal;
                                            chaîne lourde gamma2 (1-446) [Homo sapiens VH (IGHV1-8*01
                                            (100.00%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -IGHG2*01 (CH1
                                            (121-218), charnière (219-230), CH2 (231-339), CH3 (340-444),
                                            CHS (445-446)) (121-446)], (134-216')-disulfure avec la chaîne
                                            légère lambda (1'-217') [Homo sapiens V-LAMBDA (IGLV1-51*01
                                            (95.90%) -IGLJ2*01) [8.3.12] (1'-111') -IGLC2*01 (112'-217')];
                                            dimère (222-222'':223-223'':226-226'':229-229'')-tétrakisdisulfure

 dusigitumab                                inmunoglobulina G2-lambda2, anti-[Homo sapiens IGF1 (factor de
                                            crecimiento análogo a la insulina tipo 1, somatomedina C) y IGF2
                                            (factor de crecimiento análogo a la insulina tipo 2, somatomedina
                                            A)], anticuerpo monoclonal de Homo sapiens ;
                                            cadena pesada gamma2 (1-446) [Homo sapiens VH (IGHV1-8*01
                                            (100.00%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -IGHG2*01 (CH1
                                            (121-218), bisagra (219-230), CH2 (231-339), CH3 (340-444), CHS
                                            (445-446)) (121-446)], (134-216')-disulfuro con la cadena ligera
                                            lambda (1'-217') [Homo sapiens V-LAMBDA (IGLV1-51*01 (95.90%)
                                            -IGLJ2*01) [8.3.12] (1'-111') -IGLC2*01 (112'-217')]; dímero (222-
                                            222'':223-223'':226-226'':229-229'')-tetrakisdisulfuro




                                                                                                                                        285
Recommended INN: List 70                                      WHO Drug Information Vol. 27, No. 3, 2013



                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLVQSGAE VKKPGASVKV SCKASGYTFT                   SYDINWVRQA       TGQGLEWMGW        50
                           MNPNSGNTGY AQKFQGRVTM TRNTSISTAY                   MELSSLRSED       TAVYYCARDP       100
                           YYYYYGMDVW GQGTTVTVSS ASTKGPSVFP                   LAPCSRSTSE       STAALGCLVK       150
                           DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                   GLYSLSSVVT       VPSSNFGTQT       200
                           YTCNVDHKPS NTKVDKTVER KCCVECPPCP                   APPVAGPSVF       LFPPKPKDTL       250
                           MISRTPEVTC VVVDVSHEDP EVQFNWYVDG                   VEVHNAKTKP       REEQFNSTFR       300
                           VVSVLTVVHQ DWLNGKEYKC KVSNKGLPAP                   IEKTISKTKG       QPREPQVYTL       350
                           PPSREEMTKN QVSLTCLVKG FYPSDIAVEW                   ESNGQPENNY       KTTPPMLDSD       400
                           GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA                   LHNHYTQKSL       SLSPGK           446

                           Light chain / Chaîne légère / Cadena ligera
                           QSVLTQPPSV SAAPGQKVTI SCSGSSSNIE                   NNHVSWYQQL       PGTAPKLLIY 50
                           DNNKRPSGIP DRFSGSKSGT SATLGITGLQ                   TGDEADYYCE       TWDTSLSAGR 100
                           VFGGGTKLTV LGQPKAAPSV TLFPPSSEEL                   QANKATLVCL       ISDFYPGAVT 150
                           VAWKADSSPV KAGVETTTPS KQSNNKYAAS                   SYLSLTPEQW       KSHRSYSCQV 200
                           THEGSTVEKT VAPTECS                                                             217

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96        147-203       260-320 366-424
                                     22''-96'' 147''-203'' 260''-320'' 366''-424''
                           Intra-L 22'-89' 139'-198'
                                    22'''-89''' 139'''-198'''
                           Inter-H-L 134-216' 134''-216'''
                           Inter-H-H 222-222'' 223-223'' 226-226'' 229-229''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H VH N81:
                           73, 73''
                           H CH2 N84.4:
                           296, 296''



 elosulfasum alfa #
 elosulfase alfa           human N-acetylgalactosamine-6-sulfatase (chondroitinsulfatase,
                           galactose-6-sulfate sulfatase, EC=3.1.6.4) dimer (139-139')-disulfide
                           glycosylated (produced by CHO cells)

 élosulfase alfa           N-acétylgalactosamine-6-sulfatase humaine (chondroïtinesulfatase,
                           6-sulfate de galactose sulfatase, EC=3.1.6.4) (139-139')-disulfure du
                           dimère glycosylée (produite par des cellules CHO)

 elosulfasa alfa           N-acetilgalactosamina-6-sulfatasa humana (condroitinsulfatasa,
                           6-sulfato de galactosa sulfatasa, EC=3.1.6.4) (139-139')-disulfuro del
                           dímero glicosilado (producido por células CHO)

                           C5020H7574N1364O1418S34

                           Monomer / Monomère / Monómero
                           APQPPNILLL LMDDMGWGDL GVYGEPSRET                  PNLDRMAAEG       LLFPNFYSAN       50
                           PLCSPSRAAL LTGRLPIRNG FYTTNAHARN                  AYTPQEIVGG       IPDSEQLLPE       100
                           LLKKAGYVSK IVGKWHLGHR PQFHPLKHGF                  DEWFGSPNCH       FGPYDNKARP       150
                           NIPVYRDWEM VGRYYEEFPI NLKTGEANLT                  QIYLQEALDF       IKRQARHHPF       200
                           FLYWAVDATH APVYASKPFL GTSQRGRYGD                  AVREIDDSIG       KILELLQDLH       250
                           VADNTFVFFT SDNGAALISA PEQGGSNGPF                  LCGKQTTFEG       GMREPALAWW       300
                           PGHVTAGQVS HQLGSIMDLF TTSLALAGLT                  PPSDRAIDGL       NLLPTLLQGR       350
                           LMDRPIFYYR GDTLMAATLG QHKAHFWTWT                  NSWENFRQGI       DFCPGQNVSG       400
                           VTTHNLEDHT KLPLIFHLGR DPGERFPLSF                  ASAEYQEALS       RITSVVQQHQ       450
                           EALVPAQPQL NVCNWAVMNW APPGCEKLGK                  CLTPPESIPK       KCLWSH           496

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           139-139' 282-393 282'-393' 463-492 463'-492' 475-481 475'-481'

                           Modified residues / Résidus modifiés / Restos modificados
                                C               H   NH2
                             53 , 53'      O
                            3-oxoAla                 CO2H


                           Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
                           Asn-178 Asn-178' Asn-397 Asn-397'




286
WHO Drug Information Vol. 27, No. 3, 2013                                                    Recommended INN: List 70


 emapticapum pegolum
 emapticap pegol                            β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-
                                            cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-
                                            cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-uridylyl-
                                            (3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-cytidylyl-
                                            (3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-guanylyl-
                                            (3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-
                                            β-L-adenylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-
                                            uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-
                                            adenylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-
                                            cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-
                                            guanylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-
                                            uridylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-
                                            (3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanosine 6-{2-(N-[ω-
                                            methylpoly(oxyethan-1,2-diyl)]-2-{[ω-methylpoly(oxyethan-
                                            1,2-diyl)]oxy}acetamido)acetamido}hexyl hydrogen 5’-phosphate

 émapticap pégol                            β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-
                                            cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-
                                            cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-uridylyl-
                                            (3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-cytidylyl-
                                            (3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-guanylyl-
                                            (3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-
                                            β-L-adénylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-
                                            uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-
                                            adénylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-
                                            cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-
                                            guanylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-
                                            uridylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-
                                            (3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanosine 5'-hydrogénophosphate
                                            de 6-{2-(N-[ω-méthylpoly(oxyéthan-1,2-diyl)]-2-{[ω-
                                            méthylpoly(oxyéthan-1,2-diyl)]oxy}acétamido)acétamido}hexyle

 emapticap pegol                            β-L-guanilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-citidilil-
                                            (3′→5′)-β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-
                                            citidilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-citidilil-
                                            (3′→5′)-β-L-adenilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-
                                            guanilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-guanilil-
                                            (3′→5′)-β-L-citidilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-
                                            L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-adenilil-
                                            (3′→5′)-β-L-adenilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-
                                            L-citidilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-guanilil-
                                            (3′→5′)-β-L-guanilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-
                                            citidilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-citidilil-
                                            (3′→5′)-β-L-guanosina 5'-hydrógenofosfato de 6-{2-(N-[ω-
                                            metilpoli(oxietan-1,2-diil)]-2-{[ω-metilpoli(oxietan-
                                            1,2-diil)]oxi}acetamido)acetamido}hexilo

                                            C393H501N153O286P40[C2H4O]2n

                                            -L-ribo-[(3'-5')-R-pG-C-A-C-G-U-C-C-C-U-C-A-
                                              C-C-G-G-U-G-C-A-A-G-U-G-A-A-G-C-C-G-U-
                                              G-G-C-U-C-U-G-C-G]
                                                                            O
                                                                                         H
                                                   H3 C             O                    N                  CH2
                                            R- =          O         n           N
                                                       H3C              O            O
                                                              O         n




                                                                                                                         287
Recommended INN: List 70                                WHO Drug Information Vol. 27, No. 3, 2013


 emixustatum
 emixustat                 (1R)-3-amino-1-[3-(cyclohexylmethoxy)phenyl]propan-1-ol

 émixustat                 (1R)-3-amino-1-[3-(cyclohexylméthoxy)phényl]propan-1-ol

 emixustat                 (1R)-3-amino-1-[3-(ciclohexilmetoxi)fenil]propan-1-ol

                           C16H25NO2


                                                               NH 2
                                       O
                                                   H OH


 entolimodum #
 entolimod                 L-methionyl-L-arginylglycyl-L-seryl-hexa(L-histidyl)glycyl-
                           (Enterobacteria phage T7 major capsid protein 10A-(1-11)-peptidyl)-
                           L-arginyl-L-aspartyl-L-leucyl-L-tyrosyl-tetra(L-aspartyl)-L-lysyl-
                           L-aspartyl-L-prolyl-(Salmonella dublin flagellin-(1-176)-peptidyl)-
                           L-seryl-L-prolylglycyl-L-isoleucyl-L-seryl-pentaglycyl-L-isoleucyl-
                           L-leucyl-L-aspartyl-L-seryl-L-methionylglycyl-(Salmonella dublin
                           flagellin-(402-505)-peptide)

 entolimod                 L-méthionyl-L-arginylglycyl-L-séryl-hexa(L-histidyl)glycyl-(principale
                           protéine (10A) de la capside de l'Enterobacteria phage T7 -(1-11)-
                           peptidyl)-L-arginyl-L-aspartyl-L-leucyl-L-tyrosyl-tétra(L-aspartyl)-
                           L-lysyl-L-aspartyl-L-prolyl-(flagelline de Salmonella dublin -(1-176)-
                           peptidyl)-L-séryl-L-prolylglycyl-L-isoleucyl-L-séryl-pentaglycyl-
                           L-isoleucyl-L-leucyl-L-aspartyl-L-séryl-L-méthionylglycyl-(flagelline de
                           Salmonella dublin-(402-505)-peptide)

 entolimod                 L-metionil-L-arginilglicil-L-seril-hexa(L-histidil)glicil-(proteína   principal
                           (10A) de la cápsida del Enterobacteria fago T7 -(1-11)-peptidil)-
                           L-arginil-L-aspartil-L-leucil-L-tirosil-tetra(L-aspartil)-L-lisil-L-aspartil-
                           L-prolil-(flagelina de Salmonella dublin -(1-176)-peptidil)-L-seril-
                           L-prolilglicil-L-isoleucil-L-seril-pentaglicil-L-isoleucil-L-leucil-L-aspartil-
                           L-seril-L-metionilglicil-(flagelina de Salmonella dublin-(402-505)-
                           péptido)

                           C1464H2419N457O519S8
                           MRGSHHHHHH      GMASMTGGQQ    MGRDLYDDDD     KDPMAQVINT     NSLSLLTQNN     50
                           LNKSQSSLSS      AIERLSSGLR    INSAKDDAAG     QAIANRFTSN     IKGLTQASRN     100
                           ANDGISIAQT      TEGALNEINN    NLQRVRELSV     QATNGTNSDS     DLKSIQDEIQ     150
                           QRLEEIDRVS      NQTQFNGVKV    LSQDNQMKIQ     VGANDGETIT     IDLQKIDVKS     200
                           LGLDGFNVNS      PGISGGGGGI    LDSMGTLINE     DAAAAKKSTA     NPLASIDSAL     250
                           SKVDAVRSSL      GAIQNRFDSA    ITNLGNTVTN     LNSARSRIED     ADYATEVSNM     300
                           SKAQILQQAG      TSVLAQANQV    PQNVLSLLR                                    329


 eravacyclinum
 eravacycline              (4S,4aS,5aR,12aS)-4-(dimethylamino)-7-fluoro-3,10,12,12a-
                           tetrahydroxy-1,11-dioxo-9-[2-(pyrrolidin-1-yl)acetamido]-
                           1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide

 éravacycline              (4S,4aS,5aR,12aS)-4-(diméthylamino)-7-fluoro-3,10,12,12a-
                           tétrahydroxy-1,11-dioxo-9-[2-(pyrrolidin-1-yl)acétamido]-
                           1,4,4a,5,5a,6,11,12a-octahydrotétracème-2-carboxamide

 eravaciclina              (4S,4aS,5aR,12aS)-4-(dimetilamino)-7-fluoro-3,10,12,12a-
                           tetrahidroxi-1,11-dioxo-9-[2-(pirrolidin-1-il)acetamido]-
                           1,4,4a,5,5a,6,11,12a-octahidrotetraceno-2-carboxamida




288
WHO Drug Information Vol. 27, No. 3, 2013                                                      Recommended INN: List 70


                                            C27H31FN4O8

                                                                  OH   O       OH O            O
                                                              H                  OH
                                                              N
                                                  N                                                  NH2
                                                          O
                                                                                               OH
                                                                           H       H
                                                                  F                 H N        CH3
                                                                                   H3C



 evodenosonum
 evodenoson                                 methyl 4-{3-[6-amino-9-(N-cyclopropyl-β-D-ribofuranosyluronamide)-
                                            9H-purin-2-yl]prop-2-yn-1-yl}piperidine-1-carboxylate

 évodénoson                                 4-{3-[6-amino-9-(N-cyclopropyl-β-D-ribofuranosyluronamide)-
                                            9H-purin-2-yl]prop-2-yn-1-yl}pipéridine-1-carboxylate de méthyle

 evodenosón                                 4-{3-[6-amino-9-(N-ciclopropil-β-D-ribofuranosiluronamida)-9H-purin-
                                            2-il]prop-2-in-1-il}piperidina-1-carboxilato de metilo

                                            C23H29N7O6

                                                                               NH2
                                                      O                                N
                                                                           N
                                            H3C
                                                  O       N
                                                                               N       N
                                                                                                   OH
                                                                                       O
                                                                                                   OH
                                                                                   N
                                                                                   H       O


 evolocumabum #
 evolocumab                                 immunoglobulin G2-lambda, anti-[Homo sapiens PCSK9 (proprotein
                                            convertase subtilisin/kexin type 9)], Homo sapiens monoclonal
                                            antibody;
                                            gamma2 heavy chain (1-441) [Homo sapiens VH (IGHV1-18*01
                                            (93.90%) -(IGHD)-IGHJ6*01)) [8.8.8] (1-115) -IGHG2*01 (CH1 (116-
                                            213), hinge (214-225), CH2 (226-334), CH3 (335-439), CHS (440-
                                            441)) (116-441)], (129-214')-disulfide with lambda light chain (1'-
                                            215') [Homo sapiens V-LAMBDA (IGLV2-14*01 (95.90%) -IGLJ2*01)
                                            [9.3.9] (1'-109') -IGLC2*01 (110'-215')]; dimer (217-217'':218-
                                            218'':221-221'':224-224'')-tetrakisdisulfide

 évolocumab                                 immunoglobuline G2-lambda, anti-[Homo sapiens PCSK9
                                            (proprotéine convertase subtilisine/kexine type 9)], Homo sapiens
                                            anticorps monoclonal;
                                            chaîne lourde gamma2 (1-441) [Homo sapiens VH (IGHV1-18*01
                                            (93.90%) -(IGHD)-IGHJ6*01) [8.8.8] (1-115) - IGHG2*01 (CH1 (116-
                                            213), charnière (214-225), CH2 (226-334), CH3 (335-439), CHS
                                            (440-441)) (116-441)], (129-214')-disulfure avec la chaîne légère
                                            lambda (1'-215') [Homo sapiens V-LAMBDA (IGLV2-14*01 (95.90%)
                                            -IGLJ2*01) [9.3.9] (1'-109') -IGLC2*01 (110'-215')]; dimère (217-
                                            217'':218-218'':221-221'':224-224'')-tétrakisdisulfure




                                                                                                                    289
Recommended INN: List 70                                      WHO Drug Information Vol. 27, No. 3, 2013




 evolocumab                inmunoglobulina G2-lambda, anti-[Homo sapiens PCSK9
                           (proproteína convertasa subtilisina/kexina tipo 9)], anticuerpo
                           monoclonal de Homo sapiens;
                           cadena pesada gamma2 (1-441) [Homo sapiens VH (IGHV1-18*01
                           (93.90%) -(IGHD)-IGHJ6*01) [8.8.8] (1-115) - IGHG2*01 (CH1 (116-
                           213), bisagra(214-225), CH2 (226-334), CH3 (335-439), CHS (440-
                           441)) (116-441)], (129-214')-disulfuro con la cadena ligera lambda
                           (1'-215') [Homo sapiens V-LAMBDA (IGLV2-14*01 (95.90%) -
                           IGLJ2*01) [9.3.9] (1'-109') -IGLC2*01 (110'-215')]; dímero (217-
                           217'':218-218'':221-221'':224-224'')-tetrakisdisulfuro

                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLVQSGAE VKKPGASVKV SCKASGYTLT                  SYGISWVRQA       PGQGLEWMGW        50
                           VSFYNGNTNY AQKLQGRGTM TTDPSTSTAY                  MELRSLRSDD       TAVYYCARGY       100
                           GMDVWGQGTT VTVSSASTKG PSVFPLAPCS                  RSTSESTAAL       GCLVKDYFPE       150
                           PVTVSWNSGA LTSGVHTFPA VLQSSGLYSL                  SSVVTVPSSN       FGTQTYTCNV       200
                           DHKPSNTKVD KTVERKCCVE CPPCPAPPVA                  GPSVFLFPPK       PKDTLMISRT       250
                           PEVTCVVVDV SHEDPEVQFN WYVDGVEVHN                  AKTKPREEQF       NSTFRVVSVL       300
                           TVVHQDWLNG KEYKCKVSNK GLPAPIEKTI                  SKTKGQPREP       QVYTLPPSRE       350
                           EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ                  PENNYKTTPP       MLDSDGSFFL       400
                           YSKLTVDKSR WQQGNVFSCS VMHEALHNHY                  TQKSLSLSPG       K                441

                           Light chain / Chaîne légère / Cadena ligera
                           ESALTQPASV SGSPGQSITI SCTGTSSDVG                  GYNSVSWYQQ       HPGKAPKLMI 50
                           YEVSNRPSGV SNRFSGSKSG NTASLTISGL                  QAEDEADYYC       NSYTSTSMVF 100
                           GGGTKLTVLG QPKAAPSVTL FPPSSEELQA                  NKATLVCLIS       DFYPGAVTVA 150
                           WKADSSPVKA GVETTTPSKQ SNNKYAASSY                  LSLTPEQWKS       HRSYSCQVTH 200
                           EGSTVEKTVA PTECS                                                              215

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96 142-198            255-315   361-419
                                    22''-96'' 142''-198'' 255''-315'' 361''-419''
                           Intra-L 22'-90'      137'-196'
                                    22'''-90''' 137'''-196'''
                           Inter-H-L 129-214' 129''-214'''
                           Inter-H-H 217-217'' 218-218'' 221-221'' 224-224''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           291, 291''



 fedratinibum
 fedratinib                N-tert-butyl-3-[(5-methyl-2-{4-[2-(pyrrolidin-
                           1-yl)ethoxy]anilino}pyrimidin-4-yl)amino]benzenesulfonamide

 fédratinib                N-tert-butyl-3-[(5-méthyl-2-{4-[2-(pyrrolidin-
                           1-yl)éthoxy]anilino}pyrimidin-4-yl)amino]benzènesulfonamide

 fedratinib                N-terc-butil-3-[(5-metil-2-{4-[2-(pirrolidin-1-il)etoxi]anilino}pirimidin-
                           4-il)amino]bencenosulfonamida

                           C27H36N6O3S

                                             O
                                 N

                                                             NH

                                                         N        N
                                                                                          H     CH3
                                                                                          N
                                                                      N               S          CH3
                                                                      H
                                                             CH3                   O O        CH3




290
WHO Drug Information Vol. 27, No. 3, 2013                                                          Recommended INN: List 70


 filgotinibum
                                                                    6
 filgotinib                                 N-(5-{4-[(1,1-oxo-λ -thiomorpholin-
                                            4-yl)methyl]phenyl}[1,2,4]triazolo[1,5-a]pyridin-
                                            2-yl)cyclopropanecarboxamide
                                                                    6
 filgotinib                                 N-(5-{4-[(1,1-oxo-λ -thiomorpholin-
                                            4-yl)méthyl]phényl}[1,2,4]triazolo[1,5-a]pyridin-
                                            2-yl)cyclopropanecarboxamide
                                                                    6
 filgotinib                                 N-(5-{4-[(1,1-oxo-λ -tiomorfolin-4-il)metil]fenil}[1,2,4]triazolo[1,5-
                                            a]piridin-2-il)ciclopropanocarboxamida

                                            C21H23N5O3S

                                             O
                                            O S                              N        N
                                                       N                      N
                                                                                      HN
                                                                                               O

 filorexantum
 filorexant                                 [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-
                                            1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone

 filorexant                                 [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]méthyl}-2-méthylpipéridin-
                                            1-yl][5-méthyl-2-(pyrimidin-2-yl)phényl]méthanone

 filorexant                                 [(2R,5R)-5-{[(5-fluoropiridin-2-il)oxi]metil}-2-metilpiperidin-1-il][5-
                                            metil-2-(pirimidin-2-il)fenil]metanona

                                            C24H25FN4O2

                                            F                                     N        N
                                                       N                    O

                                                           O            N
                                                               H
                                                                             H
                                                                            CH3
                                                                                       CH3

 finerenonum
 finerenone                                 (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-
                                            1,4-dihydro-1,6-naphthyridine-3-carboxamide

 finérénone                                 (4S)-4-(4-cyano-2-méthoxyphényl)-5-éthoxy-2,8-diméthyl-
                                            1,4-dihydro-1,6-naphtyridine-3-carboxamide

 finerenona                                 (4S)-4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-
                                            1,6-naftiridina-3-carboxamida

                                            C21H22N4O3

                                                       CH3
                                                               H
                                                               N    CH3

                                                   N                    NH2
                                                           H
                                            H3 C       O            O
                                                                    OCH3




                                                               CN


                                                                                                                        291
Recommended INN: List 70                                        WHO Drug Information Vol. 27, No. 3, 2013




 firtecanum peglumerum
 firtecan peglumer         α-{3-[(α-N-acetylpoly-L-glutamyl)amino]propyl}-
                           ω-methoxypoly(oxyethan-1,2-diyl) where the free γ-carboxyl groups
                           are partially esterified by (4S)-4,11-diethyl-4-hydroxy-3,14-dioxo-
                           3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-
                           9-yl, partially converted to an amide with (propan-2-yl)[(propan-
                           2-yl)carbamoyl]amino and partially unchanged

 firtécan péglumère        α-{3-[(α-N-acétylpoly-L-glutamyl)amino]propyl}-
                           ω-méthoxypoly(oxyéthylène) dont certains acides γ-carboxyliques
                           sont estérifiés par le (4S)-4,11-diéthyl-4-hydroxy-3,14-dioxo-
                           3,4,12,14-tétrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoléin-
                           9-yle et d'autres amidifiés par le (propan-2-yl)[(1-propan-
                           2-yl)carbamoyl]amino

 firtecán peglúmero        α-{3-[(α-N-acetilpoli-L-glutamil)amino]propil}-ω-metoxipoli(oxietileno)
                           cuyos algunos ácidos γ-carboxílicos estan esterificados por el
                           (4S)-4,11-dietil-4-hidroxi-3,14-dioxo-3,4,12,14-tetrahidro-
                           1H-pirano[3',4':6,7]indolizino[1,2-b]quinolein-9-ilo y otros
                           amidificados por el (propan-2-il)[(propan-2-il)carbamoil]amino

                           C6H13NO2 [C5H6NO2]a [C2H4O]n (C22H19N2O5)x (C7H15N2O)y (HO)z
                           a=x+y+z
                                              R
                                     O
                                 O
                                                  H       H
                           H3C                            N              O                 CH3
                                          N                                        O
                                                                                   n
                                          H
                                                  O
                                                      a

                                                                          O
                                                          CH3
                                                                     N                 O

                                                                                           O
                                                                N
                                              O                               HO           CH3
                             R =
                                                  H3 C
                                                              CH3
                                      or              N                       or
                                      ou                                      ou           OH
                                       o                      NH               o
                                                      O             CH3
                                                          H3C


                      18
 flortanidazolum ( F)
                 18                  18
 flortanidazole ( F)       (2RS)-3-[ F]fluoro-2-{4-[(2-nitro-1H-imidazol-1-yl)methyl]-
                           1H-1,2,3-triazol-1-yl}propan-1-ol
                18                   18
 flortanidazole ( F)       (2RS)-3-[ F]fluoro-2-{4-[(2-nitro-1H-imidazol-1-yl)méthyl]-
                           1H-1,2,3-triazol-1-yl}propan-1-ol
               18                    18
 flortanidazol ( F)        (2RS)-3-[ F]fluoro-2-{4-[(2-nitro-1H-imidazol-1-il)metil]-
                           1H-1,2,3-triazol-1-il}propan-1-ol




292
WHO Drug Information Vol. 27, No. 3, 2013                                                                       Recommended INN: List 70


                                                   18
                                            C9H11 FN6O3

                                                            [18F]
                                                                                 H
                                                                                     OH
                                                                      N                     and enantiomer
                                                                                            et énantiomère
                                            N                              N                y enantiómero
                                                   N
                                                                      N
                                            O2N

                   18
 flotegatidum ( F)
              18                                                                                                             6
 flotegatide ( F)                           cyclo{L-arginylglycyl-L-α-aspartyl-D-phenylalanyl-N -[2,6-anhydro-
                                                                  18
                                            7-deoxy-7-({2-[4-(3-[ F]fluoropropyl)-1H-1,2,3-triazol-
                                            1-yl]acetyl}amino)-L-glycero-L-galacto-heptonoyl]-L-lysyl}
             18                                                                                                              6
 flotégatide ( F)                           cyclo{L-arginylglycyl-L-α-aspartyl-D-phénylalanyl-N -[2,6-anhydro-
                                                                  18
                                            7-déoxy-7-({2-[4-(3-[ F]fluoropropyl)-1H-1,2,3-triazol-
                                            1-yl]acétyl}amino)-L-glycéro-L-galacto-heptonoyl]-L-lysyl}
             18                                                                                                     6
 flotegatida ( F)                           ciclo{L-arginilglicil-L-α-aspartil-D-fenilalanil-N -[2,6-anhidro-
                                                                     18
                                            7-desoxi-7-({2-[4-(3-[ F]fluoropropil)-1H-1,2,3-triazol-
                                            1-il]acetil}amino)-L-glicero-L-galacto-heptonoil]-L-lisil}
                                                      18
                                            C41H60 FN13O13

                                                                    [18F]

                                            N
                                             N N                                                    O
                                                                    NH
                                                                                            H                            H
                                                                                                                         N
                                             O             H2N            N                             N                            CO2H
                                                                          H                             H                        H
                                                      NH                                                            O
                                                                                           HN           O
                                                                                                                        HN       O
                                                                     O
                                                            O                                   H           H
                                                                                                            N                H
                                            HO                         N
                                                                     H H
                                                                                                                    O
                                                 HO             OH
                        18
 fluorfenidinum ( F)
                18                                                          18
 fluorfenidine ( F)                         3-{2-chloro-5-[(2-[ F]fluoroethyl)sulfanyl]phenyl}-1-methyl-
                                            1-[3-(methylsulfanyl)phenyl]guanidine
                  18                                                        18
 fluorfénidine ( F)                         3-{2-chloro-5-[(2-[ F]fluoroéthyl)sulfanyl]phényl}-1-méthyl-
                                            1-[3-(méthylsulfanyl)phényl]guanidine
                  18                                                      18
 fluorfenidina ( F)                         3-{2-cloro-5-[(2-[ F]fluoroetil)sulfanil]fenil}-1-metil-
                                            1-[3-(metilsulfanil)fenil]guanidine
                                                           18
                                            C17H19Cl FN3S2

                                                                                                CH3
                                                                                      H
                                            18
                                                                S                     N         N               S
                                            [ F]                                                                    CH3
                                                                                           NH
                                                                                      Cl
                             18
 flutriciclamidum ( F)
                  18                                                                 18
 flutriciclamide ( F)                       (4S)-N,N-diethyl-9-(2-[ F]fluoroethyl)-5-methoxy-2,3,4,9-tetrahydro-
                                            1H-carbazole-4-carboxamide
                   18                                                                18
 flutriciclamide ( F)                       (4S)-N,N-diéthyl-9-(2-[ F]fluoroéthyl)-5-méthoxy-2,3,4,9-tétrahydro-
                                            1H-carbazole-4-carboxamide

                                                                                                                                            293
Recommended INN: List 70                                                                      WHO Drug Information Vol. 27, No. 3, 2013




                 18                                                                  18
 flutriciclamida ( F)                     (4S)-N,N-dietil-9-(2-[ F]fluoroetil)-5-metoxi-2,3,4,9-tetrahidro-
                                          1H-carbazol-4-carboxamida
                                                       18
                                          C20H27 FN2O2
                                                                                                   CH3
                                                                                          H
                                                                                              N            CH3
                                                                    N
                                          [18F]
                                                                                       O
                                                                                      O
                                                                                        CH3

 gandotinibum
 gandotinib                               3-[(4-chloro-2-fluorophenyl)methyl]-2-methyl-N-(5-methyl-
                                          1H-pyrazol-3-yl)-8-[(morpholin-4-yl)methyl]imidazo[1,2-b]pyridazin-
                                          6-amine

 gandotinib                               3-[(4-chloro-2-fluorophényl)méthyl]-2-méthyl-N-(5-méthyl-
                                          1H-pyrazol-3-yl)-8-[(morpholin-4-yl)méthyl]imidazo[1,2-b]pyridazin-
                                          6-amine

 gandotinib                               3-[(4-cloro-2-fluorofenil)metil]-2-metil-N-(5-metil-1H-pirazol-3-il)-
                                          8-[(morfolin-4-il)metil]imidazo[1,2-b]piridazin-6-amina

                                          C23H25ClFN7O
                                                                                     CH3
                                                                        N

                                                   N                         N                         F
                                          O                                  N

                                                            N           NH
                                                  HN                                              Cl


                                                  H3C

 hemoglobinum crosfumarilum (bovinum) #
                                           3.β92        3.β'92                                                     6.α99       6.α'99
 hemoglobin crosfumaril (bovine)          S   ,S     -bis(2-amino-2-oxoethyl)-N    ,N    -(but-
                                          2-enedioyl)bovine hemoglobulin (α2β2 tetramer)
                                           3.β92        3.β'92                                                     6.α99       6.α'99
 hémoglobine crosfumaril (bovine)         S   ,S     -bis(2-amino-2-oxoéthyl)-N   ,N    -(but-
                                          2-ènedioyl)hémoglobuline bovine (α2β2 tétramère)
                                           3.β92        3.β'92                                                   6.α99     6.α'99
 hemoglobina crosfumarilo (bovina)        S   ,S     -bis(2-amino-2-oxoetil)-N   ,N   -(but-
                                          2-enodioil)hemoglobulina bovina (α2β2 tetrámero)

                                          C2826H4406N762O802S10
                                           Alpha chain / Chaîne alpha / Cadena alfa
                                           VLSAADKGNV KAAWGKVGGH AAEYGAEALE RMFLSFPTTK TYFPHFDLSH 50
                                           GSAQVKGHGA KVAAALTKAV EHLDDLPGAL SELSDLHAHK LRVDPVNFKL 100
                                           LSHSLLVTLA SHLPSDFTPA VHASLDKFLA NVSTVLTSKY R          141

                                           Beta chain / Chaîne bêta / Cadena beta
                                           MLTAEEKAAV TAFWGKVKVD EVGGEALGRL LVVYPWTQRF FESFGDLSTA 50
                                           DAVMNNPKVK AHGKKVLDSF SNGMKHLDDL KGTFAALSEL HCDKLHVDPE 100
                                           NFKLLGNVLV VVLARNFGKE FTPVLQADFQ KVVAGVANAL AHRYH      145

                                           Modified residues / Résidus modifiés / Restos modificados
                                                        K                                                                          C
                                           99-Lys-crosfumaril-'99-Lys                                                        92 , '92   O
                                                          O
                                                                                      H
                                                                                      N       H                              H          S   NH2
                                                   H            N
                                                                H
                                                                                 O        H 2N         CO2H              H2N        CO2H
                                          H2N      CO2H


294
WHO Drug Information Vol. 27, No. 3, 2013                                                               Recommended INN: List 70




 ilorasertibum
 ilorasertib                                N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-
                                            c]pyridin-3-yl}phenyl)-N'-(3-fluorophenyl)urea

 ilorasertib                                N-(4-{4-amino-7-[1-(2-hydroxyéthyl)-1H-pyrazol-4-yl]thiéno[3,2-
                                            c]pyridin-3-yl}phényl)-N'-(3-fluorophényl)urée

 ilorasertib                                N-(4-{4-amino-7-[1-(2-hidroxietil)-1H-pirazol-4-il]tieno[3,2-c]piridin-
                                            3-il}fenil)-N'-(3-fluorofenil)urea
                                            C25H21FN6O2S

                                                                N
                                                            N
                                            HO                              S                                 F

                                                                                                    O
                                                                        N
                                                                                NH2             N        N
                                                                                                H        H

 ipatasertibum
 ipatasertib                                (2S)-2-(4-chlorophenyl)-1-{4-[(5R,7R)-7-hydroxy-5-methyl-
                                            6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl}-
                                            3-[(propan-2-yl)amino]propan-1-one

 ipatasertib                                (2S)-2-(4-chlorophényl)-1-{4-[(5R,7R)-7-hydroxy-5-méthyl-
                                            6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]pipérazin-1-yl}-
                                            3-[(propan-2-yl)amino]propan-1-one

 ipatasertib                                (2S)-2-(4-clorofenil)-1-{4-[(5R,7R)-7-hidroxi-5-metil-6,7-dihidro-
                                            5H-ciclopenta[d]pirimidin-4-il]piperazin-1-il}-3-[(propan-
                                            2-il)amino]propan-1-ona

                                            C24H32ClN5O2

                                                   CH3              O
                                                                                      H3C
                                                                                      H
                                            H3 C        N               N
                                                        H                                           H
                                                                    H            N
                                                                                                    OH
                                                                                      N     N
                                                   Cl

 lexaptepidum pegolum
 lexaptepid pegol                           β-L-guanylyl-(3'→5')-β-L-cytidylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-
                                            cytidylyl-(3'→5')-β-L-cytidylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-
                                            uridylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-guanylyl-
                                            (3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-adenylyl-
                                            (3'→5')-β-L-uridylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-adenylyl-(3'→5')-
                                            β-L-adenylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-
                                            adenylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-
                                            uridylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-
                                            guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-
                                            guanylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-guanylyl-
                                            (3'→5')-β-L-guanylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-guanylyl-
                                            (3'→5')-β-L-guanylyl-(3'→5')-β-L-adenylyl-(3'→5')-β-L-adenylyl-
                                            (3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-
                                            (3'→5')-β-L-cytidylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-cytidine
                                            6-{2-(N-[ω-methylpoly(oxyethan-1,2-diyl)]-2-{[ω-
                                            methylpoly(oxyethan-1,2-diyl)]oxy}acetamido)acetamido}hexyl
                                            hydrogen 5'-phosphate



                                                                                                                             295
Recommended INN: List 70                                   WHO Drug Information Vol. 27, No. 3, 2013




 lexaptépid pégol          β-L-guanylyl-(3'→5')-β-L-cytidylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-
                           cytidylyl-(3'→5')-β-L-cytidylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-
                           uridylyl-(3'→5')-β-L-adénylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-guanylyl-
                           (3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-adénylyl-
                           (3'→5')-β-L-uridylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-adénylyl-(3'→5')-
                           β-L-adénylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-
                           adénylyl-(3'→5')-β-L-adénylyl-(3'→5')-β-L-adénylyl-(3'→5')-β-L-
                           uridylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-adénylyl-(3'→5')-β-L-
                           guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-adénylyl-(3'→5')-β-L-
                           guanylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-uridylyl-(3'→5')-β-L-guanylyl-
                           (3'→5')-β-L-guanylyl-(3'→5')-β-L-adénylyl-(3'→5')-β-L-guanylyl-
                           (3'→5')-β-L-guanylyl-(3'→5')-β-L-adénylyl-(3'→5')-β-L-adénylyl-
                           (3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-guanylyl-
                           (3'→5')-β-L-cytidylyl-(3'→5')-β-L-guanylyl-(3'→5')-β-L-cytidine
                           5'-hydrogenophosphate de 6-{2-(N-[ω-méthylpoly(oxyéthan-
                           1,2-diyl)]-2-{[ω-méthylpoly(oxyéthan-
                           1,2-diyl)]oxy}acétamido)acétamido}hexyle

 lexaptepid pegol          β-L-guanilil-(3'→5')-β-L-citidilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-citidilil-
                           (3'→5')-β-L-citidilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-uridilil-(3'→5')-β-L-
                           adenilil-(3'→5')-β-L-uridilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-guanilil-
                           (3'→5')-β-L-guanilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-uridilil-(3'→5')-β-L-
                           uridilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-guanilil-
                           (3'→5')-β-L-uridilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-
                           adenilil-(3'→5')-β-L-uridilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-adenilil-
                           (3'→5')-β-L-guanilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-adenilil-(3'→5')-β-
                           L-guanilil-(3'→5')-β-L-uridilil-(3'→5')-β-L-uridilil-(3'→5')-β-L-guanilil-
                           (3'→5')-β-L-guanilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-guanilil-(3'→5')-β-
                           L-guanilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-adenilil-(3'→5')-β-L-guanilil-
                           (3'→5')-β-L-guanilil-(3'→5')-β-L-guanilil-(3'→5')-β-L-citidilil-(3'→5')-β-
                           L-guanilil-(3'→5')-β-L-citidina 5'-hidrógenofosfato de 6-{2-(N-[ω-
                           metilpoli(oxietan-1,2-diil)]-2-{[ω-metilpoli(oxietan-
                           1,2-diil)]oxi}acetamido)acetamido}hexilo

                           C441H548N188O309P44[C2H4O]2n

                           -L-ribo-[(3'-5')-R-pG-C-G-C-C-G-U-A-U-G-G-G-
                            A-U-U-A-A-G-U-A-A-A-U-G-A-G-G-A-G-U-U-G-
                            G-A-G-G-A-A-G-G-G-C-G-C]
                                                            O
                                                                        H
                                  H3 C             O                    N                 CH2
                           R- =          O         n            N
                                      H3C              O            O
                                             O         n




 lodelcizumabum #
 lodelcizumab              immunoglobulin G1-kappa, anti-[Homo sapiens PCSK9 (proprotein
                           convertase subtilisin/kexin type 9)], humanized monoclonal antibody;
                           gamma1 heavy chain (1-448) [humanized VH (Homo sapiens
                           IGHV1-2*05 (88.80%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -Homo
                           sapiens IGHG1*03 (CH1 (119-216), hinge (217-231), CH2 L1.3>A
                           (235), L1.2>A (236) (232-341), CH3 (342-446), CHS (447-448) (119-
                           448)], (221-213')-disulfide with kappa light chain (1'-213') [humanized
                           V-KAPPA (Homo sapiens IGKV3-20*02 (87.60%) -IGKJ2*01) [5.3.9]
                           (1'-106') -Homo sapiens IGKC*01 (107'-213')]; dimer (227-227":230-
                           230")-bisdisulfide




296
WHO Drug Information Vol. 27, No. 3, 2013                                                            Recommended INN: List 70


 lodelcizumab                               immunoglobuline G1-kappa, anti-[Homo sapiens PCSK9
                                            (proprotéine convertase subtilisine/kexine type 9)], anticorps
                                            monoclonal humanisé;
                                            chaîne lourde gamma1 (1-448) [VH humanisé (Homo sapiens
                                            IGHV1-2*05 (88.80%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) - Homo
                                            sapiens IGHG1*03 (CH1 (119-216), charnière (217-231), CH2
                                            L1.3>A (235), L1.2>A (236) (232-341), CH3 (342-446), CHS (447-
                                            448) (119-448)], (221-213')-disulfure avec la chaîne légère kappa
                                            (1'-213') [V-KAPPA humanisé (Homo sapiens IGKV3-20*02
                                            (87.60%) -IGKJ2*01) [5.3.9] (1'-106') -Homo sapiens IGKC*01 (107'-
                                            213')]; dimère (227-227":230-230")-bisdisulfure

 lodelcizumab                               inmunoglobulina G1-kappa, anti-[Homo sapiens PCSK9 (proproteína
                                            convertasa subtilisina/kexina tipo 9)], anticuerpo monoclonal
                                            humanizado;
                                            cadena pesada gamma1 (1-448) [VH humanizado (Homo sapiens
                                            IGHV1-2*05 (88.80%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) - Homo
                                            sapiens IGHG1*03 (CH1 (119-216), bisagra (217-231), CH2 L1.3>A
                                            (235), L1.2>A (236) (232-341), CH3 (342-446), CHS (447-448) (119-
                                            448)], (221-213')-disulfuro con la cadena ligera kappa (1'-213') [V-
                                            KAPPA humanizada (Homo sapiens IGKV3-20*02 (87.60%) -
                                            IGKJ2*01) [5.3.9] (1'-106') -Homo sapiens IGKC*01 (107'-213')];
                                            dímero (227-227":230-230")-bisdisulfuro
                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            QVQLVQSGAE VKKPGASVKV SCKASGYTFS                  TMYMSWVRQA       PGQGLEWMGR        50
                                            IDPANEHTNY AQKFQGRVTM TRDTSISTAY                  MELSRLTSDD       TAVYYCARSY       100
                                            YYYNMDYWGQ GTLVTVSSAS TKGPSVFPLA                  PSSKSTSGGT       AALGCLVKDY       150
                                            FPEPVTVSWN SGALTSGVHT FPAVLQSSGL                  YSLSSVVTVP       SSSLGTQTYI       200
                                            CNVNHKPSNT KVDKRVEPKS CDKTHTCPPC                  PAPEAAGGPS       VFLFPPKPKD       250
                                            TLMISRTPEV TCVVVDVSHE DPEVKFNWYV                  DGVEVHNAKT       KPREEQYNST       300
                                            YRVVSVLTVL HQDWLNGKEY KCKVSNKALP                  APIEKTISKA       KGQPREPQVY       350
                                            TLPPSREEMT KNQVSLTCLV KGFYPSDIAV                  EWESNGQPEN       NYKTTPPVLD       400
                                            SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH                  EALHNHYTQK       SLSLSPGK         448

                                            Light chain / Chaîne légère / Cadena ligera
                                            QIVLTQSPAT LSVSPGERAT LSCRASQSVS                  YMHWYQQKPG       QAPRLLIYGV 50
                                            FRRATGIPDR FSGSGSGTDF TLTIGRLEPE                  DFAVYYCLQW       SSDPPTFGQG 100
                                            TKLEIKRTVA APSVFIFPPS DEQLKSGTAS                  VVCLLNNFYP       REAKVQWKVD 150
                                            NALQSGNSQE SVTEQDSKDS TYSLSSTLTL                  SKADYEKHKV       YACEVTHQGL 200
                                            SSPVTKSFNR GEC                                                                213

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-96        145-201       262-322 368-426
                                                     22''-96'' 145''-201'' 262''-322'' 368''-426''
                                            Intra-L 23'-87' 133'-193'
                                                     23'''-87''' 133'''-193'''
                                            Inter-H-L 221-213' 221''-213'''
                                            Inter-H-H 227-227'' 230-230''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            H CH2 N84.4:
                                            298, 298''




 luminespibum
 luminespib                                 5-[2,4-dihydroxy-5-(propan-2-yl)phenyl]-N-ethyl-4-{4-[(morpholin-
                                            4-yl)methyl]phenyl}-1,2-oxazole-3-carboxamide

 luminespib                                 5-[2,4-dihydroxy-5-(propan-2-yl)phényl]-N-éthyl-4-{4-[(morpholin-
                                            4-yl)méthyl]phényl}-1,2-oxazole-3-carboxamide

 luminespib                                 5-[2,4-dihidroxi-5-(propan-2-il)fenil]-N-etil-4-{4-[(morfolin-
                                            4-il)metil]fenil}-1,2-oxazol-3-carboxamida




                                                                                                                                        297
Recommended INN: List 70                                         WHO Drug Information Vol. 27, No. 3, 2013


                           C26H31N3O5

                                      N
                           O                                 O
                                                                     NH
                                                                              CH3
                                      CH3
                                                                 N
                               H3 C                          O

                                      HO                OH

 molidustatum
 molidustat                2-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-
                           1,2-dihydro-3H-pyrazol-3-one

 molidustat                2-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-
                           1,2-dihydro-3H-pyrazol-3-one

 molidustat                2-[6-(morfolin-4-il)pirimidin-4-il]-4-(1H-1,2,3-triazol-1-il)-1,2-dihidro-
                           3H-pirazol-3-ona

                           C13H14N8O2

                                               NH                         O
                                 N             N                 N
                           N N
                                           O        N        N

 nesvacumabum #
 nesvacumab                immunoglobulin G1-kappa, anti-[Homo sapiens ANGPT2
                           (angiopoietin 2, Ang2)], Homo sapiens monoclonal antibody;
                           gamma1 heavy chain (1-452) [Homo sapiens VH (IGHV3-13*01
                           (97.90%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -IGHG1*01 (CH1 (123-
                           220), hinge 221-235), CH2 (236-345), CH3 (346-450), CHS (451-
                           452)) (123-452)], (225-214')-disulfide with kappa light chain (1'-214')
                           [Homo sapiens V-KAPPA (IGKV3-20*01 (95.80%) -IGKJ1*01) [7.3.8]
                           (1'-107') -IGKC*01 (108'-214')]; dimer (231-231'':234-234'')-
                           bisdisulfide

 nesvacumab                immunoglobuline G1-kappa, anti-[Homo sapiens ANGPT2
                           (angiopoïétine 2, Ang2)], Homo sapiens anticorps monoclonal;
                           chaîne lourde gamma1 (1-452) [Homo sapiens VH (IGHV3-13*01
                           (97.90%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -IGHG1*01 (CH1 (123-
                           220), charnière (221-235), CH2 (236-345), CH3 (346-450), CHS
                           (451-452)) (123-452)], (225-214')-disulfure avec la chaîne légère
                           kappa (1'-214') [Homo sapiens V- KAPPA (IGKV3-20*01 (95.80%) -
                           IGKJ1*01) [7.3.8] (1'-107') -IGKC*01 (108'-214')]; dimère (231-
                           231'':234-234'')-bisdisulfure

 nesvacumab                inmunoglobulina G1-kappa, anti-[Homo sapiens ANGPT2
                           (angiopoyetina 2, Ang2)], Homo sapiens anticuerpo monoclonal;
                           cadena pesada gamma1 (1-452) [Homo sapiens VH (IGHV3-13*01
                           (97.90%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -IGHG1*01 (CH1 (123-
                           220),bisagra (221-235), CH2 (236-345), CH3 (346-450), CHS (451-
                           452)) (123-452)], (225-214')-disulfuro con la cadena ligera kappa (1'-
                           214') [Homo sapiens V- KAPPA (IGKV3-20*01 (95.80%) -IGKJ1*01)
                           [7.3.8] (1'-107') -IGKC*01 (108'-214')]; dímero (231-231'':234-234'')-
                           bisdisulfuro




298
WHO Drug Information Vol. 27, No. 3, 2013                                                              Recommended INN: List 70



                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            EVQLVESGGG LVQPGGSLRL SCAASGFTFS                   SYDIHWVRQA        TGKGLEWVSA           50
                                            IGPAGDTYYP GSVKGRFTIS RENAKNSLYL                   QMNSLRAGDT        AVYYCARGLI          100
                                            TFGGLIAPFD YWGQGTLVTV SSASTKGPSV                   FPLAPSSKST        SGGTAALGCL          150
                                            VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ                   SSGLYSLSSV        VTVPSSSLGT          200
                                            QTYICNVNHK PSNTKVDKKV EPKSCDKTHT                   CPPCPAPELL        GGPSVFLFPP          250
                                            KPKDTLMISR TPEVTCVVVD VSHEDPEVKF                   NWYVDGVEVH        NAKTKPREEQ          300
                                            YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN                   KALPAPIEKT        ISKAKGQPRE          350
                                            PQVYTLPPSR DELTKNQVSL TCLVKGFYPS                   DIAVEWESNG        QPENNYKTTP          400
                                            PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC                   SVMHEALHNH        YTQKSLSLSP          450
                                            GK                                                                                       452

                                            Light chain / Chaîne légère / Cadena ligera
                                            EIVLTQSPGT LSLSPGERAT LSCRASQSVS                   STYLAWYQQK        PGQAPRLLIY 50
                                            GASSRATGIP DRFSGSGSGT DFTLTISRLE                   PEDFAVYYCQ        HYDNSQTFGQ 100
                                            GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                   SVVCLLNNFY        PREAKVQWKV 150
                                            DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                   LSKADYEKHK        VYACEVTHQG 200
                                            LSSPVTKSFN RGEC                                                                 214

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-95 149-205              266-326  372-430
                                                     22''-95'' 149''-205'' 266''-326'' 372''-430''
                                            Intra-L 23'-89' 134'-194'
                                                     23'''-89''' 134'''-194'''
                                            Inter-H-L 225-214' 225''-214'''
                                            Inter-H-H 231-231'' 234-234''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            H CH2 N84.4:
                                            302, 302''

 nonacogum gamma #
 nonacog gamma                              variant_011773 (148-T>A) of human coagulation factor IX (EC
                                            3.4.21.22, Christmas factor, plasma thromboplastin component),
                                            glycosylated (γ-glycoform)

 nonacog gamma                              variant_011773 (148-T>A) du facteur IX humain de coagulation (EC
                                            3.4.21.22, facteur Christmas, facteur antihémophile B) glycosylé
                                            (glycoforme γ)

 nonacog gamma                              variante_011773 (148-T>A) del factor IX humano de coagulación
                                            (EC 3.4.21.22, factor Christmas, factor antihemofílico B) glicosilado
                                            (glicoforma γ)

                                            C2053H3116N558O675P2S26 (peptide)
                                            Sequence / Séquence / Secuencia
                                            YNSGKLEEFV QGNLERECME EKCSFEEARE                  VFENTERTTE         FWKQYVDGDQ      50
                                            CESNPCLNGG SCKDDINSYE CWCPFGFEGK                  NCELDVTCNI         KNGRCEQFCK      100
                                            NSADNKVVCS CTEGYRLAEN QKSCEPAVPF                  PCGRVSVSQT         SKLTRAEAVF      150
                                            PDVDYVNSTE AETILDNITQ STQSFNDFTR                  VVGGEDAKPG         QFPWQVVLNG      200
                                            KVDAFCGGSI VNEKWIVTAA HCVETGVKIT                  VVAGEHNIEE         TEHTEQKRNV      250
                                            IRIIPHHNYN AAINKYNHDI ALLELDEPLV                  LNSYVTPICI         ADKEYTNIFL      300
                                            KFGSGYVSGW GRVFHKGRSA LVLQYLRVPL                  VDRATCLRST         KFTIYNNMFC      350
                                            AGFHEGGRDS CQGDSGGPHV TEVEGTSFLT                  GIISWGEECA         MKGKYGIYTK      400
                                            VSRYVNWIKE KTKLT                                                                     415

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            18-23 51-62 56-71 73-82 88-99 95-109
                                            111-124 132-289 206-222 336-350 361-389

                                            Modified residues / Résidus modifiés / Restos modificados
                                                     E                                                                      H    NH2
                                            7-8-15-17-20-21-26 HO2C         H   NH2                     D          HO2C
                                              27-30-33-36-40                                           64                        CO2H
                                               4-carboxyGlu HO2C                                  3-hydroxyAsp
                                                                                 CO2H                                       OH
                                                                                                                                 H     NH2
                                                  Y         HO       O                                 S            O       O
                                                 155             S                 H   NH2            158               P              CO2H
                                              O-sulfoTyr       O O                               O-phosphonoSer     HO OH
                                                                                        CO2H


                                            Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación (N, S*, T* )
                                            Ser-53* Ser-61* Asn-157 Thr-159* Asn-167 Thr-169* Thr-172* Thr-179*
                                            * potential sites / sites potentiels / posiciones posibles




                                                                                                                                              299
Recommended INN: List 70                                  WHO Drug Information Vol. 27, No. 3, 2013


 olaptesedum pegolum
 olaptesed pegol           β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-
                           uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-
                           (3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-
                           β-L-adenylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-
                           uridylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-
                           adenylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-
                           (3′→5′)-β-L-adenylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-
                           β-L-guanylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-
                           uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-uridylyl-
                           (3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-
                           β-L-adenylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-
                           cytidylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-
                           guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-adenylyl-(3′→5′)-β-L-
                           cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidine 6-{2-(N-[ω-
                           methylpoly(oxyethan-1,2-diyl)]-2-{[ω-methylpoly(oxyethan-
                           1,2-diyl)]oxy}acetamido)acetamido}hexyl hydrogen 5′-phosphate

 olaptésed pégol           β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-
                           uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-
                           (3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-
                           β-L-adénylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-
                           uridylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-
                           adénylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-
                           (3′→5′)-β-L-adénylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-
                           β-L-guanylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-
                           uridylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-uridylyl-
                           (3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-cytidylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-
                           β-L-adénylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-
                           cytidylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-
                           guanylyl-(3′→5′)-β-L-uridylyl-(3′→5′)-β-L-adénylyl-(3′→5′)-β-L-
                           cytidylyl-(3′→5′)-β-L-guanylyl-(3′→5′)-β-L-cytidine
                           5'-hydrogénophosphate de 6-{2-(N-[ω-méthylpoly(oxyéthan-
                           1,2-diyl)]-2-{[ω-méthylpoly(oxyéthan-
                           1,2-diyl)]oxy}acétamido)acétamido}hexyle

 olaptesed pegol           β-L-guanilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-uridilil-
                           (3′→5′)-β-L-guanilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-
                           guanilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-adenilil-
                           (3′→5′)-β-L-uridilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-
                           adenilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-uridilil-
                           (3′→5′)-β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-
                           uridilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-guanilil-
                           (3′→5′)-β-L-citidilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-
                           adenilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-citidilil-
                           (3′→5′)-β-L-uridilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-
                           uridilil-(3′→5′)-β-L-citidilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-guanilil-
                           (3′→5′)-β-L-guanilil-(3′→5′)-β-L-uridilil-(3′→5′)-β-L-adenilil-(3′→5′)-β-L-
                           citidilil-(3′→5′)-β-L-guanilil-(3′→5′)-β-L-citidina 5'-hidrógenofosfato de
                           6-{2-(N-[ω-metilpoli(oxietan-1,2-diil)]-2-{[ω-metilpoli(oxietan-
                           1,2-diil)]oxi}acetamido)acetamido}hexilo

                           C442H554N169O326P45[C2H4O]2n

                           -L-ribo-[(3'-5')-R-pG-C-G-U-G-G-U-G-U-G-A-
                           U-C-U-A-G-A-U-G-U-A-U-U-G-G-C-U-G-A-U-
                           C-C-U-A-G-U-C-A-G-G-U-A-C-G-C]

                                                           O
                                                                       H
                                  H3C             O                    N                  CH2
                           R- =         O         n            N
                                      H3C             O            O
                                            O         n



300
WHO Drug Information Vol. 27, No. 3, 2013                                                     Recommended INN: List 70




 ompinamerum
 ompinamer                                  poly{[(piperazine-1,4-diyl N-oxide)ethylene]-co-[(piperazine-
                                            1,4-diyl)ethylene]}

 ompinamère                                 poly{[(N-oxyde de pipérazine-1,4-diyl)éthylène]-co-[(pipérazine-
                                            1,4-diyl)éthylène]}

 ompinámero                                 poli{[(N-óxido de piperazina-1,4-diil)etileno]-co-[(piperazina-
                                            1,4-diil)etileno]}

                                            [[C6H12N2]x [C6H12N2O]y]n


                                                     N
                                                                        O
                                                            N
                                                                x       N
                                                                                  N
                                                                                      y
                                                                                          n

                                                   x = 8-9 , y = 1-2 , n = 8-24

 ozanezumabum #
 ozanezumab                                 immunoglobulin G1-kappa, anti-[Homo sapiens RTN4 (reticulon 4,
                                            neurite outgrowth inhibitor, NOGO), isoform A], humanized
                                            monoclonal antibody;
                                            gamma1 heavy chain (1-443) [humanized VH (Homo sapiens
                                            IGHV1-46*01 (86.50%) -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -Homo
                                            sapiens IGHG1*01 (CH1 (114-211), hinge (212-226), CH2 L1.2>A
                                            (231), G1>A (233) (227-336), CH3 (337-441), CHS (442-443) (114-
                                            443)], (216-219')-disulfide with kappa light chain (1'-219') [humanized
                                            V-KAPPA (Homo sapiens IGKV2-30*01 (80.00%) -IGKJ2*01)
                                            [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimer (222-
                                            222":225-225")-bisdisulfide

 ozanezumab                                 immunoglobuline G1-kappa, anti-[Homo sapiens RTN4 (réticulon 4,
                                            inhibiteur de la croissance des neurites, NOGO), isoforme A],
                                            anticorps monoclonal humanisé;
                                            chaîne lourde gamma1 (1-443) [VH humanisé (Homo sapiens
                                            IGHV1-46*01 (86.50%) -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -Homo
                                            sapiens IGHG1*01 (CH1 (114-211), charnière (212-226), CH2
                                            L1.2>A (231), G1>A (233) (227-336), CH3 (337-441), CHS (442-
                                            443) (114-443)], (216-219')-disulfure avec la chaîne légère kappa
                                            (1'-219') [V-KAPPA humanisé (Homo sapiens IGKV2-30*01
                                            (80.00%) -IGKJ2*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01
                                            (113'-219')]; dimère (222-222":225-225")-bisdisulfure

 ozanezumab                                 inmunoglobulina G1-kappa, anti-[Homo sapiens RTN4 (reticulon 4,
                                            inhibidor del crecimiento de las neuritas, NOGO), isoforma A],
                                            anticuerpo monoclonal humanizado;
                                            cadena pesada gamma1 (1-443) [VH humanizada (Homo sapiens
                                            IGHV1-46*01 (86.50%) -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -Homo
                                            sapiens IGHG1*01 (CH1 (114-211), bisagra (212-226), CH2 L1.2>A
                                            (231), G1>A (233) (227-336), CH3 (337-441), CHS (442-443) (114-
                                            443)], (216-219')-disulfuro con la cadena ligera kappa (1'-219') [V-
                                            KAPPA humanizada (Homo sapiens IGKV2-30*01 (80.00%) -
                                            IGKJ2*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')];
                                            dímero (222-222":225-225")-bisdisulfuro




                                                                                                                   301
Recommended INN: List 70                                          WHO Drug Information Vol. 27, No. 3, 2013




                             Heavy chain / Chaîne lourde / Cadena pesada
                             QVQLVQSGAE VKKPGASVKV SCKASGYTFT                       SYWMHWVRQA       PGQGLEWIGN     50
                             INPSNGGTNY NEKFKSKATM TRDTSTSTAY                       MELSSLRSED       TAVYYCELMQ    100
                             GYWGQGTLVT VSSASTKGPS VFPLAPSSKS                       TSGGTAALGC       LVKDYFPEPV    150
                             TVSWNSGALT SGVHTFPAVL QSSGLYSLSS                       VVTVPSSSLG       TQTYICNVNH    200
                             KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL                       AGAPSVFLFP       PKPKDTLMIS    250
                             RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV                       HNAKTKPREE       QYNSTYRVVS    300
                             VLTVLHQDWL NGKEYKCKVS NKALPAPIEK                       TISKAKGQPR       EPQVYTLPPS    350
                             RDELTKNQVS LTCLVKGFYP SDIAVEWESN                       GQPENNYKTT       PPVLDSDGSF    400
                             FLYSKLTVDK SRWQQGNVFS CSVMHEALHN                       HYTQKSLSLS       PGK           443

                             Light chain / Chaîne légère / Cadena ligera
                             DIVMTQSPLS NPVTLGQPVS ISCRSSKSLL                       YKDGKTYLNW       FLQRPGQSPQ 50
                             LLIYLMSTRA SGVPDRFSGG GSGTDFTLKI                       SRVEAEDVGV       YYCQQLVEYP 100
                             LTFGQGTKLE IKRTVAAPSV FIFPPSDEQL                       KSGTASVVCL       LNNFYPREAK 150
                             VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                       SSTLTLSKAD       YEKHKVYACE 200
                             VTHQGLSSPV TKSFNRGEC                                                               219

                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                             Intra-H 22-96 140-196              257-317  363-421
                                      22''-96'' 140''-196'' 257''-317'' 363''-421''
                             Intra-L 23'-93'      139'-199'
                                      23'''-93''' 139'''-199'''
                             Inter-H-L 216-219' 216''-219'''
                             Inter-H-H 222-222'' 225-225''

                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                             H CH2 N84.4:
                             293, 293'




 peginterferonum beta-1a #
                               2.1
 peginterferon beta-1a       N -{(2RS)-2-methyl-3-[ω-methoxypoly(oxyethylene)]propyl}human
                             interferon beta (fibroblast interferon, IFN-beta) glycosylated
                             expressed in mammalian cells
                               2.1
 péginterféron bêta-1a       N -{(2RS)-2-méthyl-3-[ω-
                             méthoxypoly(oxyéthylène)]propyl}interféron bêta humain (interféron
                             fibroblastoïde, IFN-bêta) glycosylé produit par les cellules de
                             mammifères
                               2.1
 peginterferón beta-1a       N -{(2RS)-2-metil-3-[ω-metoxipoli(oxietileno)]propil}interferón beta
                             humano (interferón fibroblastoide, IFN-beta) glicosilado producido
                             por las células de mamífero

                             C913H1417N246O256PS7 [C2H4O]n

                             Sequence / Séquence / Secuencia
                             MSYNLLGFLQ RSSNFQCQKL LWQLNGRLEY CLKDRMNFDI PEEIKQLQQF 50
                             QKEDAALTIY EMLQNIFAIF RQDSSSTGWN ETIVENLLAN VYHQINHLKT 100
                             VLEEKLEKED FTRGKLMSSL HLKRYYGRIL HYLKAKEYSH CAWTIVRVEI 150
                             LRNFYFINRL TGYLRN                                      166

                             Disulfide bridge location / Position du pont disulfure / Posicion del puente disulfuro
                             31-141

                             Modified residues / Résidus modifiés / Restos modificados
                                                and epimer at C*                        CH3
                                                et l'épimère en C*                                                OH
                                M                                                   S               S               OH
                                                y el epímero al C*
                                 1                                              H                  119          O P
                             N-pegMet                                                         O-phosphonoSer     H O
                                               O
                                         H3C             O        *         N   CO2H
                                                         n                  H                             H2N     CO2H
                                                              H       CH3



                             Glycosylation site (N) / Site de glycosylation (N) / Posicion de glicosilación (N)
                             Asn-80




302
WHO Drug Information Vol. 27, No. 3, 2013                                             Recommended INN: List 70


 pexastimogenum devacirepvecum #
 pexastimogene devacirepvec                 recombinant vaccinia virus vector (Wyeth strain) with its thymidine
                                            kinase gene de-activated by insertion of a GM-CSF (Granulocytes-
                                            macrophages colony stimulating factor) gene under the control of a
                                            synthetic early/late promoter and a beta-galactosidase gene under
                                            the control of the p7.5 early/late promoter

 pexastimogène dévacirépvec                 vecteur viral recombinant répliquant de la vaccine avec son gène de
                                            la thymidine kinase désactivé par l'insertion du gène GM-
                                            CSF(facteur de stimulation des colonies de granulocytes et de
                                            macrophages) sous le contrôle d'un promoteur synthétique précoce
                                            tardif et d'un gène de bêta-galactosidase sous le contrôle du
                                            promoteur p7.5 précoce tardif

 pexastimogén devacirepvec                  vector virus vaccinia recombinante replicante con el gen de la
                                            timidina kinasa desactivado por inserción del gen GM-CSF(factor de
                                            estimulación de colonias de granulocitos y macrófagos) bajo control
                                            de un promotor sintético precoz tardío y de un gen de beta-
                                            galactosidasa bajo control del promotor p7.5 precoz tardío



 pidilizumabum #
 pidilizumab                                immunoglobulin G1-kappa, anti-[Homo sapiens PDCD1
                                            (programmed cell death 1, PD-1, PD1, CD279)], humanized
                                            monoclonal antibody;
                                            gamma1 heavy chain (1-447) [humanized VH (Homo sapiens
                                            IGHV7-4-1*03 (83.50%) -(IGHD)-IGHJ3*01 M11>L (112)) [8.8.10] (1-
                                            117) -Homo sapiens IGHG1*03 (CH1 (118-215), hinge 216-230,
                                            CH2 (231-340), CH3 (341-445), CHS (446-447)], (220-213')-disulfide
                                            with kappa light chain (1'-213') [humanized V-KAPPA (Homo sapiens
                                            IGKV1-39*01 (75.80%) -IGKJ4*01 V9 >L (103)) [5.3.9] (1'-106') -
                                            Homo sapiens IGKC*01 (107'-213')]; dimer (226-226":229-229")-
                                            bisdisulfide

 pidilizumab                                immunoglobuline G1-kappa, anti-[Homo sapiens PDCD1 (protéine 1
                                            de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps
                                            monoclonal humanisé;
                                            chaîne lourde gamma1 (1-447) [VH humanisé (Homo sapiens
                                            IGHV7-4-1*03 (83.50%) -(IGHD)-IGHJ3*01 M11>L (112)) [8.8.10] (1-
                                            117) -Homo sapiens IGHG1*03 (CH1 (118-215), charnière 216-230,
                                            CH2 (231-340), CH3 (341-445), CHS (446-447)], (220-213')-
                                            disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA humanisé
                                            (Homo sapiens IGKV1-39*01 (75.80%) -IGKJ4*01 V9 >L (103))
                                            [5.3.9] (1'-106') -Homo sapiens IGKC*01 (107'-213')]; dimère (226-
                                            226":229-229")-bisdisulfure

 pidilizumab                                inmunoglobulina G1-kappa, anti-[Homo sapiens PDCD1 (proteína 1
                                            de muerte celular programada, PD-1, PD1, CD279)], anticuerpo
                                            monoclonal humanizado;
                                            cadena pesada gamma1 (1-447) [VH humanizado (Homo sapiens
                                            IGHV7-4-1*03 (83.50%) -(IGHD)-IGHJ3*01 M11>L (112)) [8.8.10] (1-
                                            117) -Homo sapiens IGHG1*03 (CH1 (118-215),bisagra 216-230,
                                            CH2 (231-340), CH3 (341-445), CHS (446-447)], (220-213')-
                                            disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA humanizado
                                            (Homo sapiens IGKV1-39*01 (75.80%) -IGKJ4*01 V9 >L (103))
                                            [5.3.9] (1'-106') -Homo sapiens IGKC*01 (107'-213')]; dímero (226-
                                            226":229-229")-bisdisulfuro




                                                                                                                  303
Recommended INN: List 70                                         WHO Drug Information Vol. 27, No. 3, 2013


                             Heavy chain / Chaîne lourde / Cadena pesada
                             QVQLVQSGSE LKKPGASVKI SCKASGYTFT                  NYGMNWVRQA       PGQGLQWMGW        50
                             INTDSGESTY AEEFKGRFVF SLDTSVNTAY                  LQITSLTAED       TGMYFCVRVG       100
                             YDALDYWGQG TLVTVSSAST KGPSVFPLAP                  SSKSTSGGTA       ALGCLVKDYF       150
                             PEPVTVSWNS GALTSGVHTF PAVLQSSGLY                  SLSSVVTVPS       SSLGTQTYIC       200
                             NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP                  APELLGGPSV       FLFPPKPKDT       250
                             LMISRTPEVT CVVVDVSHED PEVKFNWYVD                  GVEVHNAKTK       PREEQYNSTY       300
                             RVVSVLTVLH QDWLNGKEYK CKVSNKALPA                  PIEKTISKAK       GQPREPQVYT       350
                             LPPSREEMTK NQVSLTCLVK GFYPSDIAVE                  WESNGQPENN       YKTTPPVLDS       400
                             DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE                  ALHNHYTQKS       LSLSPGK          447

                             Light chain / Chaîne légère / Cadena ligera
                             EIVLTQSPSS LSASVGDRVT ITCSARSSVS                  YMHWFQQKPG       KAPKLWIYRT 50
                             SNLASGVPSR FSGSGSGTSY CLTINSLQPE                  DFATYYCQQR       SSFPLTFGGG 100
                             TKLEIKRTVA APSVFIFPPS DEQLKSGTAS                  VVCLLNNFYP       REAKVQWKVD 150
                             NALQSGNSQE SVTEQDSKDS TYSLSSTLTL                  SKADYEKHKV       YACEVTHQGL 200
                             SSPVTKSFNR GEC                                                                213

                             Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                             Intra-H 22-96        144-200       261-321  367-425
                                       22''-96'' 144''-200'' 261''-321'' 367''-425''
                             Intra-L 23'-87'      133'-193'
                                      23'''-87''' 133'''-193'''
                             Inter-H-L 220-213' 220''-213'''
                             Inter-H-H 226-226'' 229-229''

                             N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                             H CH2 N84.4:
                             297, 297''



 pilaralisibum
 pilaralisib                 2-amino-N-(3-{[3-(2-chloro-5-methoxyanilino)quinoxalin-
                             2-yl]sulfamoyl}phenyl)-2-methylpropanamide

 pilaralisib                 2-amino-N-(3-{[3-(2-chloro-5-méthoxyanilino)quinoxalin-
                             2-yl]sulfamoyl}phényl)-2-méthylpropanamide

 pilaralisib                 2-amino-N-(3-{[3-(2-cloro-5-metoxianilino)quinoxalin-
                             2-il]sulfamoil}fenil)-2-metilpropanamida

                             C25H25ClN6O4S

                                                                        OCH3


                                                       Cl
                                                              HN        N
                              H3C     CH3                   O O
                                            H
                                            N                S
                             H2 N                                N      N
                                                                 H
                                        O



 pinatuzumabum vedotinum #
 pinatuzumab vedotin         immunoglobulin G1-kappa auristatin E conjugate, anti-[Homo sapiens
                             CD22 (sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-
                             lymphocyte cell adhesion molecule, BL-CAM, Leu-14)], humanized
                             monoclonal antibody conjugated to auristatin E;
                             gamma1 heavy chain (1-450) [humanized VH (Homo sapiens IGHV3-
                             66*01 (79.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -Homo sapiens
                             IGHG1*03 (CH1 R120>K (217) (121-218), hinge (219-233), CH2 (234-
                             343), CH3 (344-448), CHS (449-450)) (121-450)], (223-219')-disulfide (if
                             not conjugated) with kappa light chain (1'-219') [humanized V-KAPPA
                             (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ1*01) [11.3.9] (1'-112') -
                             Homo sapiens IGKC*01 (113'-219')]; dimer (229-229":232-232")-
                             bisdisulfide; conjugated, on an average of 3 to 4 cysteinyl, to
                             monomethylauristatin E (MMAE), via a cleavable maleimidecaproyl-valyl-
                             citrullinyl-p-aminobenzylcarbamate (mc-val-cit-PABC) linker
                             For the vedotin part, please refer to the document "INN for
                             pharmaceutical substances: Names for radicals, groups and others"*.



304
WHO Drug Information Vol. 27, No. 3, 2013                                                                 Recommended INN: List 70


 pinatuzumab védotine                       immunoglobuline G1-kappa conjuguée à l'auristatine E, anti-[Homo
                                            sapiens CD22 (Ig-like lectine 2 liant l'acide sialique, SIGLEC2, SIGLEC-
                                            2, molécule d'adhésion cellulaire du lymphocyte B, BL-CAM, Leu-14)],
                                            anticorps monoclonal humanisé conjugué à l'auristatine E;
                                            chaîne lourde gamma1 (1-450) [VH humanisé (Homo sapiens IGHV3-
                                            66*01 (79.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -Homo sapiens
                                            IGHG1*03 (CH1 R120>K (217) (121-218), charnière (219-233), CH2
                                            (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-219')-
                                            disulfure (si non conjugué) avec la chaîne légère kappa (1'-219') [V-
                                            KAPPA humanisé (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ1*01)
                                            [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dimère (229-
                                            229":232-232")-bisdisulfure; conjugué, sur 3 à 4 cystéinyl en moyenne,
                                            au monométhylauristatine E (MMAE), via un linker clivable
                                            maléimidecaproyl-valyl-citrullinyl-p-aminobenzylcarbamate (mc-val-cit-
                                            PABC)
                                            Pour la partie védotine, veuillez-vous référer au document "INN for
                                            pharmaceutical substances: Names for radicals, groups and others"*.

 pinatuzumab vedotina                       inmunoglobulina G1-kappa conjugada con auristatina E, anti-[Homo
                                            sapiens CD22 (Ig-like lectine 2 que liga ácido siálico, SIGLEC2, SIGLEC-
                                            2, molécula d'adhesión celular del linfocito B, BL-CAM, Leu-14)],
                                            anticuerpo monoclonal humanizado conjugado con auristatina E;
                                            cadena pesada gamma1 (1-450) [VH humanizado (Homo sapiens
                                            IGHV3-66*01 (79.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -Homo
                                            sapiens IGHG1*03 (CH1 R120>K (217) (121-218), bisagra (219-233),
                                            CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-219')-
                                            disulfuro (si no conjugado ) con la cadena ligera kappa (1'-219') [V-
                                            KAPPA humanizado (Homo sapiens IGKV1-39*01 (80.00%) -IGKJ1*01)
                                            [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219')]; dímero (229-
                                            229":232-232")-bisdisulfuro; conjugado, en 3 - 4 restos cistenil por
                                            término medio, con monometilauristatina E (MMAE), mediante un vínculo
                                            escindible maleimidacaproil-valil-citrulinil-p-aminobencilcarbamato (mc-
                                            val-cit-PABC)
                                            Para la fracción vedotina , se pueden dirigir al documento "INN for
                                            pharmaceutical substances: Names for radicals, groups and others"*.

                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            EVQLVESGGG LVQPGGSLRL SCAASGYEFS                  RSWMNWVRQA       PGKGLEWVGR        50
                                            IYPGDGDTNY SGKFKGRFTI SADTSKNTAY                  LQMNSLRAED       TAVYYCARDG       100
                                            SSWDWYFDVW GQGTLVTVSS ASTKGPSVFP                  LAPSSKSTSG       GTAALGCLVK       150
                                            DYFPEPVTVS WNSGALTSGV HTFPAVLQSS                  GLYSLSSVVT       VPSSSLGTQT       200
                                            YICNVNHKPS NTKVDKKVEP KSCDKTHTCP                  PCPAPELLGG       PSVFLFPPKP       250
                                            KDTLMISRTP EVTCVVVDVS HEDPEVKFNW                  YVDGVEVHNA       KTKPREEQYN       300
                                            STYRVVSVLT VLHQDWLNGK EYKCKVSNKA                  LPAPIEKTIS       KAKGQPREPQ       350
                                            VYTLPPSREE MTKNQVSLTC LVKGFYPSDI                  AVEWESNGQP       ENNYKTTPPV       400
                                            LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV                  MHEALHNHYT       QKSLSLSPGK       450

                                            Light chain / Chaîne légère / Cadena ligera
                                            DIQMTQSPSS LSASVGDRVT ITCRSSQSIV                  HSVGNTFLEW       YQQKPGKAPK 50
                                            LLIYKVSNRF SGVPSRFSGS GSGTDFTLTI                  SSLQPEDFAT       YYCFQGSQFP 100
                                            YTFGQGTKVE IKRTVAAPSV FIFPPSDEQL                  KSGTASVVCL       LNNFYPREAK 150
                                            VQWKVDNALQ SGNSQESVTE QDSKDSTYSL                  SSTLTLSKAD       YEKHKVYACE 200
                                            VTHQGLSSPV TKSFNRGEC                                                          219

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-96        147-203       264-324   370-428
                                                      22''-96'' 147''-203'' 264''-324'' 370''-428''
                                            Intra-L 23'-93'       139'-199'
                                                     23'''-93''' 139'''-199'''
                                            Inter-H-L* 223-219' 223''-219'''
                                            Inter-H-H* 229-229'' 232-232''
                                            *Two or three of the inter-chain disulfide bridges are not present, the antibody being
                                            conjugated to an average of 3 to 4 drug linkers each via a thioether bond.
                                            * Deux ou trois des ponts disulfure inter-chaines ne sont pas présents, l'anticorps étant
                                            conjugué à une moyenne de 3 à 4 linker-principe actif chacun via une liaison thioéther.
                                            * Faltan dos o tres puentes disulfuro inter-catenarios por estar el anticuerpo conjugado,
                                            con sendos enlaces tioéter, a una media de 3 a 4 conectores de principio activo.

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            H CH2 N84.4:
                                            300, 300'' but lacking carbohydrate/hydrate de carbone manquant/ falta hidrato de carbono

                                            Other post-translational modifications
                                            Autres modifications post-traductionnelles
                                            Otras modificaciones post-traduccionales
                                            Lacking H chain C-terminal lysine (CHS K2>del)




                                                                                                                                              305
Recommended INN: List 70                                 WHO Drug Information Vol. 27, No. 3, 2013




 piromelatinum
 piromelatine                N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-4-oxo-4H-pyran-2-carboxamide

 piromélatine                N-[2-(5-méthoxy-1H-indol-3-yl)éthyl]-4-oxo-4H-pyran-2-carboxamide

 piromelatina                N-[2-(5-metoxi-1H-indol-3-il)etil]-4-oxo-4H-piran-2-carboxamida

                             C17H16N2O4

                                    HN               O
                                                                  O
                                                 N
                                                 H
                                                          O
                             H3CO



 polatuzumabum vedotinum #
 polatuzumab vedotin         immunoglobulin G1-kappa auristatin E conjugate, anti-[Homo
                             sapiens CD79B (immunoglobulin-associated CD79 beta)],
                             humanized monoclonal antibody conjugated to auristatin E;
                             gamma1 heavy chain (1-447) [humanized VH (Homo sapiens
                             IGHV3-66*01 (79.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -Homo
                             sapiens IGHG1*03 (CH1 R120>K (214) (121-218), hinge (219-233),
                             CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (220-
                             218')-disulfide (if not conjugated) with kappa light chain (1'-218')
                             [humanized V-KAPPA (Homo sapiens IGKV1-39*01 (80.00%) -
                             IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-218')];
                             dimer (226-226":229-229")-bisdisulfide; conjugated, on an average
                             of 3 to 4 cysteinyl, to monomethylauristatin E (MMAE), via a
                             cleavable maleimidecaproyl-valyl-citrullinyl-p-aminobenzylcarbamate
                             (mc-val-cit-PABC) linker
                             For the vedotin part, please refer to the document "INN for
                             pharmaceutical substances: Names for radicals, groups and
                             others"*.

 polatuzumab védotine        immunoglobuline G1-kappa conjuguée à l'auristatine E, anti-[Homo
                             sapiens CD79B (CD79 bêta associé à l'immunoglobuline)], anticorps
                             monoclonal humanisé conjugué à l'auristatine E;
                             chaîne lourde gamma1 (1-447) [VH humanisé (Homo sapiens
                             IGHV3-66*01 (79.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -Homo
                             sapiens IGHG1*03 (CH1 R120>K (214) (121-218), charnière (219-
                             233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)],
                             (220-218')-disulfure (si non conjugué) avec la chaîne légère kappa
                             (1'-218') [V-KAPPA humanisé (Homo sapiens IGKV1-39*01
                             (80.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01
                             (113'-218')]; dimère (226-226":229-229")-bisdisulfure; conjugué, sur
                             3 à 4 cystéinyl en moyenne, au monométhylauristatine E (MMAE),
                             via un linker clivable maléimidecaproyl-valyl-citrullinyl-p-
                             aminobenzylcarbamate (mc-val-cit-PABC)
                             Pour la partie védotine, veuillez-vous référer au document "INN for
                             pharmaceutical substances: Names for radicals, groups and
                             others"*.




306
WHO Drug Information Vol. 27, No. 3, 2013                                                            Recommended INN: List 70


 polatuzumab vedotina                       inmunoglobulina G1-kappa conjugada con auristatina E, anti-[Homo
                                            sapiens CD79B (CD79 beta asociado a la inmunoglobulina)],
                                            anticuerpo monoclonal humanizado conjugado con auristatina E;
                                            cadena pesada gamma1 (1-447) [VH humanizado (Homo sapiens
                                            IGHV3-66*01 (79.60%) -(IGHD)-IGHJ4*01) [8.8.13] (1-120) -Homo
                                            sapiens IGHG1*03 (CH1 R120>K (214) (121-218), bisagra (219-
                                            233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)],
                                            (220-218')-disulfuro (si no está conjugado ) con la cadena ligera
                                            kappa (1'-218') [V-KAPPA humanizado (Homo sapiens IGKV1-39*01
                                            (80.00%) -IGKJ1*01) [11.3.9] (1'-112') -Homo sapiens IGKC*01
                                            (113'-218')]; dímero (226-226":229-229")-bisdisulfuro; conjugado, en
                                            3 - 4 restos cisteinil por término medio, con monometilauristatina E
                                            (MMAE), mediante un vínculo escindible maleimidacaproil-valil-
                                            citrulinil-p-aminobencilcarbamato (mc-val-cit-PABC)
                                            Para la fracción vedotina se pueden referir al documento "INN for
                                            pharmaceutical substances: Names for radicals, groups and
                                            others"*.

                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            EVQLVESGGG LVQPGGSLRL SCAASGYTFS                  SYWIEWVRQA       PGKGLEWIGE        50
                                            ILPGGGDTNY NEIFKGRATF SADTSKNTAY                  LQMNSLRAED       TAVYYCTRRV       100
                                            PIRLDYWGQG TLVTVSSAST KGPSVFPLAP                  SSKSTSGGTA       ALGCLVKDYF       150
                                            PEPVTVSWNS GALTSGVHTF PAVLQSSGLY                  SLSSVVTVPS       SSLGTQTYIC       200
                                            NVNHKPSNTK VDKKVEPKSC DKTHTCPPCP                  APELLGGPSV       FLFPPKPKDT       250
                                            LMISRTPEVT CVVVDVSHED PEVKFNWYVD                  GVEVHNAKTK       PREEQYNSTY       300
                                            RVVSVLTVLH QDWLNGKEYK CKVSNKALPA                  PIEKTISKAK       GQPREPQVYT       350
                                            LPPSREEMTK NQVSLTCLVK GFYPSDIAVE                  WESNGQPENN       YKTTPPVLDS       400
                                            DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE                  ALHNHYTQKS       LSLSPGK          447

                                            Light chain / Chaîne légère / Cadena ligera
                                            DIQLTQSPSS LSASVGDRVT ITCKASQSVD                  YEGDSFLNWY       QQKPGKAPKL 50
                                            LIYAASNLES GVPSRFSGSG SGTDFTLTIS                  SLQPEDFATY       YCQQSNEDPL 100
                                            TFGQGTKVEI KRTVAAPSVF IFPPSDEQLK                  SGTASVVCLL       NNFYPREAKV 150
                                            QWKVDNALQS GNSQESVTEQ DSKDSTYSLS                  STLTLSKADY       EKHKVYACEV 200
                                            THQGLSSPVT KSFNRGEC                                                           218

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-96        144-200       261-321   367-425
                                                      22''-96'' 147''-203'' 261''-321'' 367''-425''
                                            Intra-L 23'-92' 138'-198'
                                                     23'''-92''' 138'''-198'''
                                            Inter-H-L* 220-218' 220''-218'''
                                            Inter-H-H* 226-226'' 229-229''
                                            *Two or three of the inter-chain disulfide bridges are not present, the antibody being
                                            conjugated to an average of 3 to 4 drug linkers each via a thioether bond.
                                            * Deux ou trois des ponts disulfure inter-chaines ne sont pas présents, l'anticorps étant
                                            conjugué à une moyenne de 3 à 4 linker-principe actif chacun via une liaison thioéther.
                                            * Faltan dos o tres puentes disulfuro inter-catenarios por estar el anticuerpo conjugado,
                                            con sendos enlaces tioéter, a una media de 3 a 4 conectores de principio activo.

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            H CH2 N84.4:
                                            297, 297'' but lacking carbohydrate/hydrate de carbone manquant/ falta hidrato de carbono

                                            Other post-translational modifications
                                            Autres modifications post-traductionnelles
                                            Otras modificaciones post-traduccionales
                                            Lacking H chain C-terminal lysine (CHS K2>del)



 poziotinibum
 poziotinib                                 1-(4-{[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-
                                            6-yl]oxy}piperidin-1-yl)prop-2-en-1-one

 poziotinib                                 1-(4-{[4-(3,4-dichloro-2-fluoroanilino)-7-méthoxyquinazolin-
                                            6-yl]oxy}pipéridin-1-yl)prop-2-èn-1-one

 poziotinib                                 1-(4-{[4-(3,4-dicloro-2-fluoroanilino)-7-metoxiquinazolin-
                                            6-il]oxi}piperidin-1-il)prop-2-en-1-ona




                                                                                                                                        307
Recommended INN: List 70                                            WHO Drug Information Vol. 27, No. 3, 2013


                           C23H21Cl2FN4O3
                                        O                  CH3
                           H2C                             O                  N
                                             N
                                                                                   N
                                                           O                            F
                                                                            HN                   Cl


                                                                                                 Cl

 pritoxaximabum #
 pritoxaximab              immunoglobulin G1-kappa, anti-[shiga toxin-producing Escherichia
                           coli (STEC) shiga toxin type 1 (stx1), B subunit)], chimeric
                           monoclonal antibody;
                           gamma1 heavy chain (1-454) [Mus musculus VH (IGHV1-12*01 -
                           (IGHD)-IGHJ2*01) [8.8.15] (1-122) -linker (123-124) -Homo sapiens
                           IGHG1*01 (CH1 (125-222), hinge (223-237), CH2 (238-347), CH3
                           (348-452), CHS (453-454)) (125-454)], (227-214')-disulfide with
                           kappa light chain (1'-214') [Mus musculus V-KAPPA (IGKV6-23*01 -
                           IGKJ5*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')];
                           dimer (233-233'':236-236'')-bisdisulfide

 pritoxaximab              immunoglobuline G1-kappa, anti-[sous-unité B de la toxine type 1
                           shiga (stx1) d'Escherichia coli produisant des shiga-toxines (STEC)],
                           anticorps monoclonal chimérique;
                           chaîne lourde gamma1 (1-454) [Mus musculus VH (IGHV1-12*01 -
                           (IGHD)-IGHJ2*01) [8.8.15] (1-122) -linker (123-124) -Homo sapiens
                           IGHG1*01 (CH1 (125-222), charnière (223-237), CH2 (238-347),
                           CH3 (348-452), CHS (453-454)) (125-454)], (227-214')-disulfure
                           avec la chaîne légère kappa (1'-214') [Mus musculus V-KAPPA
                           (IGKV6-23*01 -IGKJ5*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01
                           (108'-214')]; dimère (233-233'':236-236'')-bisdisulfure

 pritoxaximab              inmunoglobulina G1-kappa, anti-[subunidad B de la toxina tipo 1
                           shiga (stx1) de Escherichia coli productor de toxinas shiga (STEC)],
                           anticuerpo monoclonal quimérico;
                           cadena pesada gamma1 (1-454) [Mus musculus VH (IGHV1-12*01 -
                           (IGHD)-IGHJ2*01) [8.8.15] (1-122) -vínculo (123-124) -Homo
                           sapiens IGHG1*01 (CH1 (125-222), bisagra (223-237), CH2 (238-
                           347), CH3 (348-452), CHS (453-454)) (125-454)], (227-214')-
                           disulfuro con la cadena ligera kappa (1'-214') [Mus musculus
                           V-KAPPA (IGKV6-23*01 -IGKJ5*01) [6.3.9] (1'-107') -Homo sapiens
                           IGKC*01 (108'-214')]; dímero (233-233'':236-236'')-bisdisulfuro
                           Heavy chain / Chaîne lourde / Cadena pesada
                           QVQLQESGAE LVRSGASVRM SCKASGYTFT                  SYNMHWVKQT       PGQGLEWIGY        50
                           IYPGNGGTNY IQKFKGKAIL TADTSSSTAY                  MQISSLTSED       SAVYFCTRSP       100
                           SHYSSDPYFD YWGQGTTLTV SSEFASTKGP                  SVFPLAPSSK       STSGGTAALG       150
                           CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV                  LQSSGLYSLS       SVVTVPSSSL       200
                           GTQTYICNVN HKPSNTKVDK KVEPKSCDKT                  HTCPPCPAPE       LLGGPSVFLF       250
                           PPKPKDTLMI SRTPEVTCVV VDVSHEDPEV                  KFNWYVDGVE       VHNAKTKPRE       300
                           EQYNSTYRVV SVLTVLHQDW LNGKEYKCKV                  SNKALPAPIE       KTISKAKGQP       350
                           REPQVYTLPP SRDELTKNQV SLTCLVKGFY                  PSDIAVEWES       NGQPENNYKT       400
                           TPPVLDSDGS FFLYSKLTVD KSRWQQGNVF                  SCSVMHEALH       NHYTQKSLSL       450
                           SPGK                                                                                454

                           Light chain / Chaîne légère / Cadena ligera
                           DIVMSQSHKF MSTSVGDRVS ITCKASQDVG                  TAVAWYQQNP       GQSPKFLIYW 50
                           ASTRHTGVPD RFTGSGSGTD FTLTITNVQS                  EDLADYFCQQ       YSSYPLTFGA 100
                           GTSLELKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                           DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                           LSSPVTKSFN RGEC                                                               214

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96 151-207            268-328    374-432
                                    22''-96'' 151''-207'' 268''-328'' 374''-432''
                           Intra-L 23'-88'      134'-194'
                                    23'''-88''' 134'''-194'''
                           Inter-H-L 227-214' 227''-214'''
                           Inter-H-H 233-233'' 236-236''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           304, 304''


308
WHO Drug Information Vol. 27, No. 3, 2013                                                            Recommended INN: List 70




 ramaterceptum #
 ramatercept                                fusion protein for immune applications (FPIA) comprising Homo
                                            sapiens ACVR2B (activin A receptor type IIB, ActR-IIB) fragment,
                                            fused with Homo sapiens immunoglobulin G1 Fc fragment;
                                            Homo sapiens ACVR2B precursor fragment 20-134 (1-115) -triglycyl
                                            (116-118) -Homo sapiens IGHG1*03 H-CH2-CH3 fragment (hinge 8-
                                            15 (119-126), CH2 A115>V (226) (127-236), CH3 (237-341), CHS
                                            (342-343)) (119-343); dimer (122-122':125-125')-bisdisulfide

 ramatercept                                protéine de fusion pour applications immunitaires (FPIA) comprenant
                                            un fragment d'Homo sapiens ACVR2B (récepteur de type IIB de
                                            l'activine A, ActR-IIB), fusionné au fragment Fc de l'Homo sapiens
                                            immunoglobuline G1;
                                            Homo sapiens ACVR2B fragment 20-134 du précurseur (1-115) -
                                            triglycyl (116-118) -Homo sapiens IGHG1*03 fragment H-CH2-CH3
                                            (charnière 8-15 (119-126), CH2 A115>V (226) (127-236), CH3 (237-
                                            341), CHS (342-343)) (119-343)]; dimère (122-122':125-125')-
                                            bisdisulfure

 ramatercept                                proteína de fusión para aplicaciones inmunitarias (FPIA) que
                                            comprende un fragmento de Homo sapiens ACVR2B (receptor de
                                            tipo IIB de la activina A, ActR-IIB), fusionado con el fragmento Fc de
                                            la Homo sapiens inmunoglobulina G1;
                                            Homo sapiens ACVR2B fragmento 20-134 del precursor (1-115) -
                                            triglicil (116-118) -Homo sapiens IGHG1*03 fragmento H-CH2-CH3
                                            (bisagra 8-15 (119-126), CH2 A115>V (226) (127-236), CH3 (237-
                                            341), CHS (342-343)) (119-343)]; dímero (122-122':125-125')-
                                            bisdisulfuro
                                            Fused chain / Chaîne fusionnée / Cadena fusionada
                                            GRGEAETREC IYYNANWELE RTNQSGLERC EGEQDKRLHC                        YASWRNSSGT        50
                                            IELVKKGCWL DDFNCYDRQE CVATEENPQV YFCCCEGNFC                        NERFTHLPEA       100
                                            GGPEVTYEPP PTAPTGGGTH TCPPCPAPEL LGGPSVFLFP                        PKPKDTLMIS       150
                                            RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE                        QYNSTYRVVS       200
                                            VLTVLHQDWL NGKEYKCKVS NKALPVPIEK TISKAKGQPR                        EPQVYTLPPS       250
                                            REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT                        PPVLDSDGSF       300
                                            FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS                        PGK              343

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-chain 10-40 30-58 65-84 71-83 85-90 157-217 263-321
                                                         10'-40' 30'-58' 65'-84' 71'-83' 85'-90' 157'-217' 263'-321'
                                            Inter-chains 122-122' 125-125'

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            23, 46, 193 (CH2 N84.4)
                                            23', 46', 193' (CH2 N84.4)




 rebastinibum
 rebastinib                                 4-[4-({[3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-
                                            5-yl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridin-
                                            2-carboxamide

 rébastinib                                 4-(4-{[3-tert-butyl-1-(quinoléin-6-yl)-1H-pyrazol-
                                            5-yl]carbamoyl}amino)-3-fluorophénoxy)-N-méthylpyridin-
                                            2-carboxamide

 rebastinib                                 4-[4-({[3-terc-butil-1-(quinolin-6-il)-1H-pirazol-5-il]carbamoil}amino)-
                                            3-fluorofenoxi]-N-metilpiridin-2-carboxamida




                                                                                                                                       309
Recommended INN: List 70                                       WHO Drug Information Vol. 27, No. 3, 2013


                           C30H28FN7O3

                                                                           N


                                 H
                           O     N
                                     CH3
                                                      H        H
                                                      N        N       N
                           N
                                                                           N
                                                           O
                                     O                F                        CH3
                                                                               CH3
                                                                   H3 C

 recilisibum
 recilisib                 4-[(1E)-2-{[(4-chlorophenyl)methyl]sulfonyl}ethenyl]benzoic acid

 récilisib                 acide 4-[(1E)-2-{[(4-chlorophényl)méthyl]sulfonyl}éthényl]benzoïque

 recilisib                 ácido 4-[(1E)-2-{[(4-clorofenil)metil]sulfonil}etenil]benzoico

                           C16H13ClO4S

                                                                       CO2H


                                             S
                                            O O
                           Cl

 revexepridum
 revexepride               4-amino-5-chloro-N-{[(3S,4S)-3-hydroxy-
                           1-(3-methoxypropyl)piperidin-4-yl]methyl}-2,2-dimethyl-2,3-dihydro-
                           1-benzofuran-7-carboxamide

 révexépride               4-amino-5-chloro-N-{[(3S,4S)-3-hydroxy-
                           1-(3-méthoxypropyl)pipéridin-4-yl]méthyl}-2,2-diméthyl-2,3-dihydro-
                           1-benzofurane-7-carboxamide

 revexeprida               4-amino-5-cloro-N-{[(3S,4S)-3-hidroxi-1-(3-metoxipropil)piperidin-
                           4-il]metil}-2,2-dimetil-2,3-dihidro-1-benzofuran-7-carboxamida

                           C21H32ClN3O4

                                            O
                            Cl
                                                 N                 N
                                                 H H
                           H2N                         H
                                            O              OH                   O CH3

                                                CH3
                                     H 3C


 roxadustatum
 roxadustat                N-[(4-hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl]glycine

 roxadustat                N-[(4-hydroxy-1-méthyl-7-phénoxyisoquinoléin-3-yl)carbonyl]glycine

 roxadustat                N-[(4-hidroxi-1-metil-7-fenoxiisoquinolin-3-il)carbonil]glicina




310
WHO Drug Information Vol. 27, No. 3, 2013                                                     Recommended INN: List 70


                                            C19H16N2O5

                                                                    CH3
                                                    O
                                                                         N
                                                                                 H
                                                                                 N     CO2H

                                                                    OH       O


 saroglitazarum
 saroglitazar                               (2S)-2-ethoxy-3-[4-(2-{2-methyl-5-[4-(methylsulfanyl)phenyl]-
                                            1H-pyrrol-1-yl}ethoxy)phenyl]propanoic acid

 saroglitazar                               acide (2S)-2-éthoxy-3-[4-(2-{2-méthyl-5-[4-(méthylsulfanyl)phényl]-
                                            1H-pyrrol-1-yl}éthoxy)phényl]propanoïque

 saroglitazar                               ácido (2S)-2-etoxi-3-[4-(2-{2-metil-5-[4-(metilsulfanil)fenil]-1H-pirrol-
                                            1-il}etoxi)fenil]propanoico

                                            C25H29NO4S

                                            H3CS



                                                                                       CH3
                                                                O
                                                      N                              H O

                                                          CH3                          CO2H



 seribantumabum #
 seribantumab                               immunoglobulin G2-lambda7, anti-[Homo sapiens ERBB3 (receptor
                                            tyrosine-protein kinase erbB-3, HER3)], Homo sapiens monoclonal
                                            antibody;
                                            gamma2 heavy chain (1-445) [Homo sapiens VH (IGHV3-23*01
                                            (90.80%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG2*01 (CH1 (120-
                                            217), hinge (218-229), CH2 (230-338), CH3 (339-443), CHS (444-
                                            445)) (120-445)], (133-216')-disulfide with lambda light chain (1'-
                                            217') [Homo sapiens V-LAMBDA (IGLV2-23*02 (94.90%) -IGLJ2*01
                                            L9>V (108) [9.3.11] (1'-111') -IGLC7*01 (100.00%) (112'-217')];
                                            dimer (221-221'':222-222'':225-225'':228-228'')-tetrakisdisulfide

 séribantumab                               immunoglobuline G2-lambda7, anti-[Homo sapiens ERBB3
                                            (récepteur tyrosine-protéine kinase erbB3, HER3)], Homo sapiens
                                            anticorps monoclonal;
                                            chaîne lourde gamma2 (1-445) [Homo sapiens VH (IGHV3-23*01
                                            (90.80%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG2*01 (CH1 (120-
                                            217), charnière (218-229), CH2 (230-338), CH3 (339-443), CHS
                                            (444-445)) (120-445)], (133-216')-disulfure avec la chaîne légère
                                            lambda (1'-217') [Homo sapiens V- LAMBDA (IGLV2-23*02 (94.90%)
                                            -IGLJ2*01 L9>V (108) [9.3.11] (1'-111') -IGLC7*01 (100.00%) (112'-
                                            217')]; dimère (221-221'':222-222'':225-225'':228-228'')-
                                            tétrakisdisulfure




                                                                                                                        311
Recommended INN: List 70                                     WHO Drug Information Vol. 27, No. 3, 2013


 seribantumab              inmunoglobulina G2-lambda7, anti-[Homo sapiens ERBB3 (receptor
                           tirosina-proteína kinasa erbB3, HER3)], anticuerpo monoclonal de
                           Homo sapiens;
                           cadena pesada gamma2 (1-445) [Homo sapiens VH (IGHV3-23*01
                           (90.80%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG2*01 (CH1 (120-
                           217), bisagra(218-229), CH2 (230-338), CH3 (339-443), CHS (444-
                           445)) (120-445)], (133-216')-disulfuro con la cadena ligera lambda
                           (1'-217') [Homo sapiens V- LAMBDA (IGLV2-23*02 (94.90%) -
                           IGLJ2*01 L9>V (108) [9.3.11] (1'-111') -IGLC7*01 (100.00%) (112'-
                           217')]; dímero (221-221'':222-222'':225-225'':228-228'')-
                           tetrakisdisulfuro
                           Heavy chain / Chaîne lourde / Cadena pesada
                           EVQLLESGGG LVQPGGSLRL SCAASGFTFS                  HYVMAWVRQA       PGKGLEWVSS        50
                           ISSSGGWTLY ADSVKGRFTI SRDNSKNTLY                  LQMNSLRAED       TAVYYCTRGL       100
                           KMATIFDYWG QGTLVTVSSA STKGPSVFPL                  APCSRSTSES       TAALGCLVKD       150
                           YFPEPVTVSW NSGALTSGVH TFPAVLQSSG                  LYSLSSVVTV       PSSNFGTQTY       200
                           TCNVDHKPSN TKVDKTVERK CCVECPPCPA                  PPVAGPSVFL       FPPKPKDTLM       250
                           ISRTPEVTCV VVDVSHEDPE VQFNWYVDGV                  EVHNAKTKPR       EEQFNSTFRV       300
                           VSVLTVVHQD WLNGKEYKCK VSNKGLPAPI                  EKTISKTKGQ       PREPQVYTLP       350
                           PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE                  SNGQPENNYK       TTPPMLDSDG       400
                           SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL                  HNHYTQKSLS       LSPGK            445

                           Light chain / Chaîne légère / Cadena ligera
                           QSALTQPASV SGSPGQSITI SCTGTSSDVG                  SYNVVSWYQQ       HPGKAPKLII 50
                           YEVSQRPSGV SNRFSGSKSG NTASLTISGL                  QTEDEADYYC       CSYAGSSIFV 100
                           IFGGGTKVTV LGQPKAAPSV TLFPPSSEEL                  QANKATLVCL       VSDFYPGAVT 150
                           VAWKADGSPV KVGVETTKPS KQSNNKYAAS                  SYLSLTPEQW       KSHRSYSCRV 200
                           THEGSTVEKT VAPAECS                                                            217

                           Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                           Intra-H 22-96       146-202        259-319  365-423
                                    22''-96'' 146''-202'' 259''-319'' 365''-423''
                           Intra-L 22'-90'      139'-198'
                                    22'''-90''' 139'''-198'''
                           Inter-H-L 133-216' 133''-216'''
                           Inter-H-H 221-221'' 222-222'' 225-225'' 228-228''

                           N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                           H CH2 N84.4:
                           295, 295''



 setoxaximabum #
 setoxaximab               immunoglobulin G1-kappa, anti-[shiga toxin-producing Escherichia
                           coli (STEC) shiga toxin type 2 (stx2), A subunit)], chimeric
                           monoclonal antibody;
                           gamma1 heavy chain (1-451) [Mus musculus VH (IGHV1-39*01 -
                           (IGHD)-IGHJ1*01) [8.8.12] (1-119) -linker (120-121) -Homo sapiens
                           IGHG1*01 (CH1 (122-219), hinge (220-234), CH2 (235-344), CH3
                           (345-449), CHS (450-451) (122-451)], (224-220')-disulfide with
                           kappa light chain (1'-220') [Mus musculus V-KAPPA (IGKV8-30*01 -
                           IGKJ5*01) [12.3.9] (1'-113') -Homo sapiens IGKC*01 (114'-220')];
                           dimer (230-230'':233-233'')-bisdisulfide

 sétoxaximab               immunoglobuline G1-kappa, anti-[sous-unité A de la toxine type 2
                           shiga (stx2) d'Escherichia coli produisant des shiga-toxines (STEC)],
                           anticorps monoclonal chimérique;
                           chaîne lourde gamma1 (1-451) [Mus musculus VH (IGHV1-39*01 -
                           (IGHD)-IGHJ1*01) [8.8.12] (1-119) -linker (120-121) -Homo sapiens
                           IGHG1*01 (CH1 (122-219), charnière (220-234), CH2 (235-344),
                           CH3 (345-449), CHS (450-451)) (122-451)], (224-220')-disulfure
                           avec la chaîne légère kappa (1'-220') [Mus musculus V-KAPPA
                           (IGKV8-30*01 -IGKJ5*01) [12.3.9] (1'-113') -Homo sapiens IGKC*01
                           (114'-220')]; (230-230'':233-233'')-bisdisulfure




312
WHO Drug Information Vol. 27, No. 3, 2013                                                             Recommended INN: List 70




 setoxaximab                                inmunoglobulina G1-kappa, anti-[subunidad A de la toxina tipo 2
                                            shiga (stx2) de Escherichia coli productor de toxinas shiga (STEC)],
                                            anticuerpo monoclonal quimérico;
                                            cadena pesada gamma1 (1-451) [Mus musculus VH (IGHV1-39*01 -
                                            (IGHD)-IGHJ1*01) [8.8.12] (1-119) -vínculo(120-121) -Homo sapiens
                                            IGHG1*01 (CH1 (122-219), bisagra (220-234), CH2 (235-344), CH3
                                            (345-449), CHS (450-451)) (122-451)], (224-220')-disulfuro con la
                                            cadena ligera kappa (1'-220') [Mus musculus V-KAPPA (IGKV8-
                                            30*01 -IGKJ5*01) [12.3.9] (1'-113') -Homo sapiens IGKC*01 (114'-
                                            220')]; (230-230'':233-233'')-bisdisulfura

                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            EVQLQQPGPE LEKPGASVKL SCKASGYSFT                  DYNMNWVKQN       NGESLEWIGK        50
                                            IDPYYGGPSY NQKFKDKATL TVDKSSSTAY                  MQLKSLTSED       SAVYYCTRGG       100
                                            NRDWYFDVWG AGTTLTVSAE FASTKGPSVF                  PLAPSSKSTS       GGTAALGCLV       150
                                            KDYFPEPVTV SWNSGALTSG VHTFPAVLQS                  SGLYSLSSVV       TVPSSSLGTQ       200
                                            TYICNVNHKP SNTKVDKKVE PKSCDKTHTC                  PPCPAPELLG       GPSVFLFPPK       250
                                            PKDTLMISRT PEVTCVVVDV SHEDPEVKFN                  WYVDGVEVHN       AKTKPREEQY       300
                                            NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK                  ALPAPIEKTI       SKAKGQPREP       350
                                            QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD                  IAVEWESNGQ       PENNYKTTPP       400
                                            VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS                  VMHEALHNHY       TQKSLSLSPG       450
                                            K                                                                                   451

                                            Light chain / Chaîne légère / Cadena ligera
                                            DIVLSQSPSS LVVSVGEKVT MSCKSSQSLL                  YSRNQKNYLA       WYQQKPGQSP 50
                                            KVLIYWASTR ESGVPDRLTG SGSGTDFTLT                  ISSVKAEDLA       VYYCQQYYSY 100
                                            PLTFGAGTKL ELKRTVAAPS VFIFPPSDEQ                  LKSGTASVVC       LLNNFYPREA 150
                                            KVQWKVDNAL QSGNSQESVT EQDSKDSTYS                  LSSTLTLSKA       DYEKHKVYAC 200
                                            EVTHQGLSSP VTKSFNRGEC                                                         220

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-96 148-204              265-325  371-429
                                                     22''-96'' 148''-204'' 265''-325'' 371''-429''
                                            Intra-L 23'-94' 140'-200'
                                                     23'''-94''' 140'''-200'''
                                            Inter-H-L 224-220' 224''-220'''
                                            Inter-H-H 230-230'' 233-233''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            H CH2 N84.4:
                                            301, 301''



 sofosbuvirum
 sofosbuvir                                 propan-2-yl N-[(S)-{[(2R,3R,4R,5R)-5-(2,4-dioxo-
                                            3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyloxolan-
                                            2-yl]methoxy}phenoxyphosphoryl]-L-alaninate

 sofosbuvir                                 N-[(S)-{[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-
                                            4-fluoro-3-hydroxy-4-méthyloxolan-
                                            2-yl]méthoxy}phénoxyphosphoryl]-L-alaninate de propan-2-yle

 sofosbuvir                                 N-[(S)-{[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihidropirimidin-1(2H)-il)-
                                            4-fluoro-3-hidroxi-4-metiloxolan-2-il]metoxi}fenoxifosforil]-L-alaninato
                                            de propan-2-ilo

                                            C22H29FN3O9P

                                                              NH                       O
                                                  N           N                N
                                            N N
                                                         O         N      N




                                                                                                                                         313
Recommended INN: List 70                                 WHO Drug Information Vol. 27, No. 3, 2013


 tecemotidum
 tecemotide                human mucin-1 (carcinoma-associated mucin, episialin, CD227)-
                           (107-131)-peptide (sequence 40 times repeated) fusion protein with
                           6-N-hexadecanoyl-L-lysylglycine

 técémotide                mucine-1 humaine (mucine associée au carcinome, épisialine,
                           CD227)-(107-131)-peptide (fragment présent 40 fois) protéine de
                           fusion avec la 6-N-hexadécanoyl-L-lysylglycine

 tecemotida                mucina-1 humana (mucina asociada al carcinoma, episialina,
                           CD227)-(107-131)-péptido (fragmento presente 40 veces) proteína
                           de fusión con la 6-N-hexadecanoil-L-lisilglicina

                           C124H203N33O38

                           Sequence / Séquence / Secuencia
                           STAPPAHGVT SAPDTRPAPG STAPPKG                    27

                           Modified residue / Résidu modifié / Resto modificado
                                 K                       O              H   NH2
                                26              H3 C
                            palmityl-Lys                14   N               CO2H
                                                             H


 telmapitantum
 telmapitant               (5R,8S)-8-({(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}methyl)-
                           8-phenyl-1,3,7-triazaspiro[4.5]decane-2,4-dione

 telmapitant               (5R,8S)-8-({(1R)-1-[3,5-bis(trifluorométhyl)phényl]éthoxy}méthyl)-
                           8-phényl-1,3,7-triazaspiro[4.5]décane-2,4-dione

 telmapitant               (5R,8S)-8-({(1R)-1-[3,5-bis(trifluorometil)fenil]etoxi}metil)-8-fenil-
                           1,3,7-triazaspiro[4.5]decano-2,4-diona

                           C24H23F6N3O3

                               O
                                     NH
                               HN                      CF3
                                            O


                                       NH
                                            O
                                                             CF3
                                            H    CH3



 tildrakizumabum #
 tildrakizumab             immunoglobulin G1-kappa, anti-[Homo sapiens IL23A (interleukin 23
                           alpha subunit (p19), IL-23A)], humanized monoclonal antibody;
                           gamma1 heavy chain (1-446) [humanized VH (Homo sapiens
                           IGHV1-18*01 (81.60%) -(IGHD)-IGHJ4*01)) [8.8.9] (1-116) -Homo
                           sapiens IGHG1*01 (CH1 (117-214, hinge (215-229), CH2 (230-339),
                           CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfide with
                           kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens
                           IGKV1-39*01 (85.30%) -IGKJ1*01) [6.3.9] (1'-107') -Homo sapiens
                           IGKC*01 (108'-214')]; dimer (225-225":228-228")-bisdisulfide




314
WHO Drug Information Vol. 27, No. 3, 2013                                                            Recommended INN: List 70




 tildrakizumab                              immunoglobuline G1-kappa, anti-[Homo sapiens IL23A (sous-unité
                                            alpha (p19) de l'interleukine 23, IL-23A)], anticorps monoclonal
                                            humanisé;
                                            chaîne lourde gamma1 (1-446) [VH humanisé (Homo sapiens
                                            IGHV1-18*01 (81.60%) -(IGHD)-IGHJ4*01)) [8.8.9] (1-116) -Homo
                                            sapiens IGHG1*01 (CH1 (117-214, charnière (215-229), CH2 (230-
                                            339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-
                                            disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé
                                            (Homo sapiens IGKV1-39*01 (85.30%) -IGKJ1*01) [6.3.9] (1'-107') -
                                            Homo sapiens IGKC*01 (108'-214')]; dimère (225-225":228-228")-
                                            bisdisulfure

 tildrakizumab                              inmunoglobulina G1-kappa, anti-[Homo sapiens IL23A (subunidad
                                            alfa (p19) de la interleukina 23, IL-23A)], anticuerpo monoclonal
                                            humanizado;
                                            cadena pesada gamma1 (1-446) [VH humanizado (Homo sapiens
                                            IGHV1-18*01 (81.60%) -(IGHD)-IGHJ4*01)) [8.8.9] (1-116) -Homo
                                            sapiens IGHG1*01 (CH1 (117-214, bisagra (215-229), CH2 (230-
                                            339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-
                                            disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado
                                            (Homo sapiens IGKV1-39*01 (85.30%) -IGKJ1*01) [6.3.9] (1'-107') -
                                            Homo sapiens IGKC*01 (108'-214')]; dímero (225-225":228-228")-
                                            bisdisulfuro

                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            QVQLVQSGAE VKKPGASVKV SCKASGYIFI                  TYWMTWVRQA       PGQGLEWMGQ        50
                                            IFPASGSADY NEKFEGRVTM TTDTSTSTAY                  MELRSLRSDD       TAVYYCARGG       100
                                            GGFAYWGQGT LVTVSSASTK GPSVFPLAPS                  SKSTSGGTAA       LGCLVKDYFP       150
                                            EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS                  LSSVVTVPSS       SLGTQTYICN       200
                                            VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA                  PELLGGPSVF       LFPPKPKDTL       250
                                            MISRTPEVTC VVVDVSHEDP EVKFNWYVDG                  VEVHNAKTKP       REEQYNSTYR       300
                                            VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP                  IEKTISKAKG       QPREPQVYTL       350
                                            PPSRDELTKN QVSLTCLVKG FYPSDIAVEW                  ESNGQPENNY       KTTPPVLDSD       400
                                            GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA                  LHNHYTQKSL       SLSPGK           446

                                            Light chain / Chaîne légère / Cadena ligera
                                            DIQMTQSPSS LSASVGDRVT ITCRTSENIY                  SYLAWYQQKP       GKAPKLLIYN 50
                                            AKTLAEGVPS RFSGSGSGTD FTLTISSLQP                  EDFATYYCQH       HYGIPFTFGQ 100
                                            GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA                  SVVCLLNNFY       PREAKVQWKV 150
                                            DNALQSGNSQ ESVTEQDSKD STYSLSSTLT                  LSKADYEKHK       VYACEVTHQG 200
                                            LSSPVTKSFN RGEC                                                               214

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            Intra-H 22-96 143-199              260-320  366-424
                                                     22''-96'' 143''-199'' 260''-320'' 366''-424''
                                            Intra-L 23'-88'      134'-194'
                                                     23'''-88''' 134'''-194'''
                                            Inter-H-L 219-214' 219''-214'''
                                            Inter-H-H 225-225'' 228-228''

                                            N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
                                            H CH2 N84.4:
                                            296, 296''




 tomicoratum
 tomicorat                                  4-{5-[(5-fluoro-2-methylphenoxy)methyl]-2,2,4-trimethyl-
                                            1,2-dihydroquinolin-6-yl}-3-methoxyphenyl furan-2-carboxylate

 tomicorat                                  furane-2-carboxylate de 4-{5-[(5-fluoro-2-méthylphénoxy)méthyl]-
                                            2,2,4-triméthyl-1,2-dihydroquinoléin-6-yl}-3-méthoxyphényle




                                                                                                                                        315
Recommended INN: List 70                                 WHO Drug Information Vol. 27, No. 3, 2013




 tomicorat                     furan-2-carboxilato de 4-{5-[(5-fluoro-2-metilfenoxi)metil]-
                               2,2,4-trimetil-1,2-dihidroquinolin-6-il}-3-metoxifenilo

                               C32H30FNO5

                                H3C
                                              CH3 H3C
                               H3C
                                   HN
                                                    O             F

                                                              O

                                          H3CO            O
                                                                  O




 turoctocogum alfa pegolum #
 turoctocog alfa pegol         human coagulation factor VIII-(1-750)-(1638-1648)-peptide
                               compound with human coagulation factor VIIIa light chain,
                               glycosylated and pegylated;
                                 3.750
                               O      -[α-methylpoly(oxyethylene) 5-(acetylamino)-2,5-dideoxy-
                               D-glycero-β-D-galacto-non-2-ulopyranosylonate-(2→4)-α-D-
                               galactopyranosyl-(1→4)-2-(acetylamino)-2-deoxy-α-D-
                               galactopyranosyl]-des-(751-1637)-human coagulation factor VIII-(1-
                               1648)-peptide containing 92 kDa factor VIIIa heavy chain compound
                               with human coagulation factor VIIIa light chain glycosylated
                               (glycoform alfa produced in CHO cells)

 turoctocog alfa pégol         facteur VIII de coagulation humain-(1-750)-(1638-1648)-peptide
                               associé à la chaîne légère du facteur VIIIa de coagulation humain
                               glycosylés et pégylés
                                 3.750
                               O      -[5-(acétylamino)-2,5-didéoxy-D-glycéro-β-D-galacto-non-
                               2-ulopyranosylonate de α-méthylpoly(oxyéthylène)-(2→4)-α-D-
                               galactopyranosyl-(1→4)-2-(acétylamino)-2-déoxy-α-D-
                               galactopyranosyl]-dès-(751-1637)-facteur VIII de coagulation
                               humain-(1-1648)-peptide contenant la chaîne lourde de 92 kDa du
                               factor VIIIa associé à la chaîne légère du facteur VIIIa de
                               coagulation humain glycosylés (glycoforme alfa produit par des
                               cellules CHO)

 turoctocog alfa pegol         factor VIII de coagulación humano-(1-750)-(1638-1648)-péptido
                               asociado a la cadena ligera del factor VIIIa de coagulación humano
                               glicosilados y pegilados;
                                 3.750
                               O      -[5-(acetilamino)-2,5-didesoxi-D-glicero-β-d-galacto-non-
                               2-ulopiranosilonato de α-metilpoli(oxietileno)-(2→4)-α-D-
                               galactopiranosil-(1→4)-2-(acetlamino)-2-desoxi-α-D-
                               galactopiranosil]-des-(751-1637)-factor VIII de coagulación humano-
                               (1-1648)-péptido que contiene la cadena pesada de 92 kDa del
                               factor VIIIa asociado a la cadena ligera del factor VIIIa de
                               coagulación humano glicosilados (glicoforma alfa producido por
                               células CHO)




316
WHO Drug Information Vol. 27, No. 3, 2013                                                                Recommended INN: List 70




                                            Heavy chain / Chaîne lourde / Cadena pesada
                                            ATRRYYLGAV ELSWDYMQSD LGELPVDARF                         PPRVPKSFPF     NTSVVYKKTL        50
                                            FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV                         YDTVVITLKN     MASHPVSLHA        100
                                            VGVSYWKASE GAEYDDQTSQ REKEDDKVFP                         GGSHTYVWQV     LKENGPMASD        150
                                            PLCLTYSYLS HVDLVKDLNS GLIGALLVCR                         EGSLAKEKTQ     TLHKFILLFA        200
                                            VFDEGKSWHS ETKNSLMQDR DAASARAWPK                         MHTVNGYVNR     SLPGLIGCHR        250
                                            KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN                         HRQASLEISP     ITFLTAQTLL        300
                                            MDLGQFLLFC HISSHQHDGM EAYVKVDSCP                         EEPQLRMKNN     EEAEDYDDDL        350
                                            TDSEMDVVRF DDDNSPSFIQ IRSVAKKHPK                         TWVHYIAAEE     EDWDYAPLVL        400
                                            APDDRSYKSQ YLNNGPQRIG RKYKKVRFMA                         YTDETFKTRE     AIQHESGILG        450
                                            PLLYGEVGDT LLIIFKNQAS RPYNIYPHGI                         TDVRPLYSRR     LPKGVKHLKD        500
                                            FPILPGEIFK YKWTVTVEDG PTKSDPRCLT                         RYYSSFVNME     RDLASGLIGP        550
                                            LLICYKESVD QRGNQIMSDK RNVILFSVFD                         ENRSWYLTEN     IQRFLPNPAG        600
                                            VQLEDPEFQA SNIMHSINGY VFDSLQLSVC                         LHEVAYWYIL     SIGAQTDFLS        650
                                            VFFSGYTFKH KMVYEDTLTL FPFSGETVFM                         SMENPGLWIL     GCHNSDFRNR        700
                                            GMTALLKVSS CDKNTGDYYE DSYEDISAYL                         LSKNNAIEPR     SFSQNSRHPS        750
                                            QNPPVLKRHQ R                                                                              761

                                            Light chain / Chaîne légère / Cadena ligera
                                                                                                                            EI        1650
                                            TRTTLQSDQE      EIDYDDTISV         EMKKEDFDIY            DEDENQSPRS     FQKKTRHYFI        1700
                                            AAVERLWDYG      MSSSPHVLRN         RAQSGSVPQF            KKVVFQEFTD     GSFTQPLYRG        1750
                                            ELNEHLGLLG      PYIRAEVEDN         IMVTFRNQAS            RPYSFYSSLI     SYEEDQRQGA        1800
                                            EPRKNFVKPN      ETKTYFWKVQ         HHMAPTKDEF            DCKAWAYFSD     VDLEKDVHSG        1850
                                            LIGPLLVCHT      NTLNPAHGRQ         VTVQEFALFF            TIFDETKSWY     FTENMERNCR        1900
                                            APCNIQMEDP      TFKENYRFHA         INGYIMDTLP            GLVMAQDQRI     RWYLLSMGSN        1950
                                            ENIHSIHFSG      HVFTVRKKEE         YKMALYNLYP            GVFETVEMLP     SKAGIWRVEC        2000
                                            LIGEHLHAGM      STLFLVYSNK         CQTPLGMASG            HIRDFQITAS     GQYGQWAPKL        2050
                                            ARLHYSGSIN      AWSTKEPFSW         IKVDLLAPMI            IHGIKTQGAR     QKFSSLYISQ        2100
                                            FIIMYSLDGK      KWQTYRGNST         GTLMVFFGNV            DSSGIKHNIF     NPPIIARYIR        2150
                                            LHPTHYSIRS      TLRMELMGCD         LNSCSMPLGM            ESKAISDAQI     TASSYFTNMF        2200
                                            ATWSPSKARL      HLQGRSNAWR         PQVNNPKEWL            QVDFQKTMKV     TGVTTQGVKS        2250
                                            LLTSMYVKEF      LISSSQDGHQ         WTLFFQNGKV            KVFQGNQDSF     TPVVNSLDPP        2300
                                            LLTRYLRIHP      QSWVHQIALR         MEVLGCEAQD            LY                               2332

                                            Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
                                            153-179 248-329 528-554 630-711 1832-1858 1899-1903 2021-2169 2174-2326

                                            Sulfated residues (Y) / Résidus sulfatés (Y) / Restos sulfatados (Y)
                                            Tyr-346 Tyr-718 Tyr-719 Tyr-723 Tyr-1664 Tyr-1680

                                            Modified residue / Résidu modifié / Resto modificado                            CH3
                                                                     O                                                O
                                                                                                                            n
                                                   S
                                                  750                         NH   OH       HO         OH O     O    OH O
                                             O-(PEG-Glyc)Ser        H3C                                                         CH3
                                                                H         O             O                 O               NH
                                                                               O                 O             O
                                                            H2 N     CO2H                                             H
                                                                                        OH                OH
                                                                                                               HO               OH
                                                                                                                      OH
                                            Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
                                            Asn-41 Asn-239 Asn-1810 Asn-2118




 ulodesinum
 ulodesine                                  7-{[(3R,4R)-3-hydroxy-4-(hydroxymethyl)pyrrolidin-1-yl]methyl}-
                                            1,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one

 ulodésine                                  7-{[(3R,4R)-3-hydroxy-4-(hydroxyméthyl)pyrrolidin-1-yl]méthyl}-
                                            1,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one

 ulodesina                                  7-{[(3R,4R)-3-hidroxi-4-(hidroximetil)pirrolidin-1-il]metil}-1,5-dihidro-
                                            4H-pirrolo[3,2-d]pirimidin-4-ona




                                                                                                                                             317
Recommended INN: List 70                                   WHO Drug Information Vol. 27, No. 3, 2013


                           C12H16N4O3

                               O
                                       H
                                       N
                           N

                               N
                               H                      OH
                                              N

                                                       OH

 vibegronum
 vibegron                  (6S)-N-[4-({(2S,5R)-5-[(R)-hydroxy(phenyl)methyl]pyrrolidin-
                           2-yl}methyl)phenyl]-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-
                           6-carboxamide

 vibégron                  (6S)-N-[4-({(2S,5R)-5-[(R)-hydroxyphénylméthyl]pyrrolidin-
                           2-yl}méthyl)phényl]-4-oxo-4,6,7,8-tétrahydropyrrolo[1,2-a]pyrimidine-
                           6-carboxamide

 vibegrón                  (6S)-N-[4-({(2S,5R)-5-[(R)-hidroxi(fenil)metil]pirrolidin-2-il}metil)fenil]-
                           4-oxo-4,6,7,8-tetrahidropirrolo[1,2-a]pirimidina-6-carboxamida

                           C26H28N4O3

                                   H OH
                                              H
                                              N
                                                                  O
                                       H          H
                                                                N
                                                                H H
                                                                       N
                                                                             N
                                                                   O

 voxtalisibum
 voxtalisib                2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-3-yl)pyrido[2,3-d]pyrimidin-
                           7(8H)-one

 voxtalisib                2-amino-8-éthyl-4-méthyl-6-(1H-pyrazol-3-yl)pyrido[2,3-d]pyrimidin-
                           7(8H)-one

 voxtalisib                2-amino-8-etil-4-metil-6-(1H-pirazol-3-il)pirido[2,3-d]pirimidin-
                           7(8H)-ona

                           C13H14N6O

                                       CH3
                                                           NH
                                   N                  N

                           H2N         N      N   O

                                       H3 C

 zamicastatum
 zamicastat                5-(2-(benzylamino)ethyl)-1-[(3R)-6,8-difluoro-3,4-dihydro-
                           2H-1-benzopyran-3-yl)-1,3-dihydro-2H-imidazole-2-thione

 zamicastat                5-[2-(benzylamino)éthyl]-1-[(3R)-6,8-difluoro-3,4-dihydro-
                           2H-1-benzopyran-3-yl]-1,3-dihydro-2H-imidazole-2-thione

 zamicastat                5-(2-(bencilamino)etil)-1-[(3R)-6,8-difluoro-3,4-dihidro-
                           2H-1-benzopiran-3-il)-1,3-dihidro-2H-imidazol-2-tiona



318
WHO Drug Information Vol. 27, No. 3, 2013                                  Recommended INN: List 70


                                              C21H21F2N3OS

                                                    F
                                                         O       S

                                                                     NH
                                                                 N
                                              F
                                                             H

                                                                     NH




# Electronic structure available on Mednet: http://mednet.who.int/
# Structure électronique disponible sur Mednet: http://mednet.who.int/
# Estructura electrónica disponible en Mednet: http://mednet.who.int/

* http://www.who.int/entity/medicines/services/inn/Radical_Book_2012.pdf




                                                                                                319
Recommended INN: List 70                                                    WHO Drug Information Vol. 27, No. 3, 2013




                                    AMENDMENTS TO PREVIOUS LISTS
                           MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
                               MODIFICACIONES A LAS LISTAS ANTERIORES



Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 36
(Información Farmacéutica OMS, Vol. 10, No. 3, 1996)

p. 147    suprimáse                   insertese
          fasidotril                  fasidotrilo



Recommended International Nonproprietary Names (Rec. INN): List 58
Dénominations communes internationales recommandées (DCI Rec.): Liste 58
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 58
(WHO Drug Information, Vol. 21, No. 3, 2007)

p. 255   methylnaltrexonii bromidum
         methylnaltrexone bromide      replace the chemical name by the following one
                                       (17RS)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-
                                       14-morphinanium bromide




Recommended International Nonproprietary Names (Rec. INN): List 62
Dénominations communes internationales recommendées (DCI Rec.): Liste 62
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 62
(WHO Drug Information, Vol. 23, No. 3, 2009)

p. 248   fidaxomicinum
         fidaxomicin              replace the chemical name by the following one
         fidaxomicina             sustitúyase el nombre químico por el siguiente
                                  (3E,5E,8S,9E,11S,12R,13E,15E,18S)-3-{[(6-deoxy-4-O-(3,5-dichloro-2-ethyl-4,6-
                                  dihydroxybenzoyl)-2-O-methyl-β-D-mannopyranosyl)oxy]methyl}-12-{[6-deoxy-5-C-
                                  methyl-4-O-(2-methylpropanoyl)-β-D-lyxo-hexopyranosyl]oxy}-11-ethyl-8-hydroxy-18-
                                  [(1R)-1-hydroxyethyl]-9,13,15-trimethyloxacyclooctadeca-3,5,9,13,15-pentaen-2-one

                                  (3E,5E,8S,9E,11S,12R,13E,15E,18S)-3-{[(6-desoxi-4-O-(3,5-dicloro-2-etil-4,6-
                                  dihidroxibenzoil)-2-O-metil-β-D-manopiranosil)oxi]metil}-12-{[6-desoxi-5-C-metil-4-O-
                                  (2-metilpropanoil)-β-D-lixo-hexopiranosil]oxi}-11-etil-8-hidroxi-18-[(1R)-1-hidroxietil]-
                                  9,13,15-trimetiloxaciclooctadeca-3,5,9,13,15-pentaen-2-ona




320
    WHO Drug Information Vol. 27, No. 3, 2013                                                Recommended INN: List 70




Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales
The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical
Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical
Substances will be reproduced in proposed INN lists only.
Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les
substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales
applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées.
El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias
farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para
sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.




                                                                                                                    321
